AUTHOR INDEX

VOLUME 19

Abe, Yashuo, 188
Adams, Cynthia B., 117
Adams, Katherine F., 226
Al-Badr, Abdullah A., 29
Albers, Ann C., 917
Amadeo, José A., 352
Andersen, Burton R., 284
Anderson, R., 495
Andrews, Fred A., 110
Anthony, Bascom F., 1075
Anton, P., 12
Armstrong, Emma Lee, 346
Arnold, K., 8, 12, 925
Arnold, Wolfgang, 44
Aronoff, George R., 306, 575
Arvin, Ann M., 193
Atkin-Thor, Elisabet, 450

Badal, R. E., 122
Baer, Herman, 598, 842
Baker, C. N., 122, 716
Bakker-Woudenberg, Irma A. J. M., 76
Baldwin, Jack N., 571
Barbour, Alan G., 316
Barnett, D., 1024
Barnishan, Jean, 357
Barriere, Steven L., 326
Barry, A. L., 122
Baughn, Robert E., 117
Bayer, Arnold S., 179
Beggs, William H., 110
Beneke, Everett S., 1078
Bergan, Tom, 1029
Bergeron, Michel G., 101, 761
Bermúdez, Ramón H., 352
Bernheimer, Harriet, 675
Bernstein, David, 620
Beskid, George, 424
Bhattacharyya, Mukti N., 666
Bhuwapathanapun, S., 209
Bille, Jacques, 381
Blachman, Uzy, 144
Blum, M. Robert, 608
Bodey, Gerald P., 639, 1037
Bodey, Gerald P., Sr., 139
Bogerd, Laurie, 139
Bolton, W. Klinz, 613, 821
Borowski, Edward, 238
Botta, Giuseppe A., 891
Bourgault, Anne-Marie, 513
Bower, Robert R., 454
Brady, Eileen, 937
Brajtburg, Janina, 199
Bredesen, Jan E., 82
Brown, James E., 248
Brown, Nita S., 139, 1037
Brown, R. E., 234
Brown, Stephen D., 930
Browne, Michael J., 712
Brumfitt, W., 1067
Bruun, Johan N., 82
Bryan, L. E., 958
Bryan, Lawrence E., 705
Buffa, Dionigia, 891
Bundtzen, Robert W., 443
Butler, T. F., 934
Butler, Thomas, 328

Calberg-Bacq, Claire-Michèle, 477
Calderwood, Stephen B., 549
Came, P. E., 470
Campbell, Donald E., 672
Campos, Jaime, 826
Caplan, Ellis, 620
Cappetta, Audrey J., 424
Carabateas, P. M., 470
Carrizosa, Jaime, 773
Carter, Mary Jo, 218
Casillas, Edmundo, 987
Cerra, Frank B., 147, 859
Chau, P. Y., 8, 925
Chen, Young C., 365
Cherubin, Charles C., 794
Chevli, Rekha, 589
Christensen, E. F., 1024
Clahsen, Joan C., 1086
Clark, Alice M., 337
Clark, David, 370
Claveau, Suzanne, 101
Cleeland, Roy, 424
Cobbs, C. G., 114
Cohen, Albert, 1004
Colleran, Emer, 266
Collins, Cynthia D., 248
Comty, Christina, 605
Connor, James D., 608
Cooper, Ronald H., 256
Coppens, L., 72
Corner, Thomas R., 1082
Cornwall, Howard A., 867
Corrado, Michael L., 794
Costerton, J. W., 1056
Counts, George W., 190
Coyette, Jacques, 477
Craig, William A., 443
Crankshaw, Daune, 110
Crossley, Kent B., 740
Cummings, Marinella, 675
Cynamon, Michael H., 205
Czerwinski, Anthony W., 461

Davis, Patrick J., 465
de Bos, P., 76
DeFelice, Richard, 1073
De Grandis, S., 593
De Grandis, Stephanie A., 831
Del Bene, Victor E., 248
Delsarte, Anne, 477
de Repentigny, Louis, 645
Deresinski, Stanley C., 534
DeStefano, Eugene, 937
Devaud, Marlyse, 766
DeVoe, I. W., 911
Devriese, Luc A., 274
de Vries-Hospers, Hilly G., 813
Diana, G. D., 470
Dillon, Jo-Anne R., 952
Dinwiddie, Charles B., Jr., 306
Dixon, Peter, 328
Doern, Gary V., 930
Donbrow, Max, 696
Donowitz, Gerald R., 613
Drach, John C., 682
Drew, W. Lawrence, 332
Drews, Jürgen, 386
Drusano, George, 335
Duangmani, Chiraphun, 290
Dubovi, E. J., 649
Duck, Peter, 952
Dutta, Gunindra N., 274

Ebright, Jack R., 980
Echeverria, Peter, 290
Edwards, John E., Jr., 179, 196
Ehret, J., 436
Eickhoff, T. C., 436
Eikman, Edward A., 534
Eisenberg, Arthur D., 807
Elberg, Svetlana, 199
Eley, Adrian, 66
Eliopoulos, George M., 789
Elliott, A. M., 114
Elnima, Elamin I., 29
Engel, Robert, 678
Ennis, Herbert L., 657
Eskin, Barnet, 424
Estey, Elihu H., 639

Facklam, R. R., 716
Fass, Robert J., 357, 359, 361
Fathey, Shadia, 941
Faway, Michel, 477
Fekety, Robert, 980
Fennell, Robert, 598
Ferrara, Elaine A., 1042
Fierer, Joshua, 342
Fillastre, J. P., 965
Fineberg, Naomi S., 306
Fisher, John F., 218

Fitch, Coy D., 589
Fitzgerald, Gerald R., 562
Fitzgerald, Robert H., Jr., 851
Fleming, P. C., 593, 831
Fletcher, Ronald D., 917
Fondy, Thomas P., 678
Fong, Kei-Lai L., 139
Forbes, Martin, 634
Forlenza, Susan W., 144
Forward, Kevin R., 513
Francke, Elliot L., 298
Franker, Colin K., 166
French, Margaret A., 147
Frère, Jean-Marie, 477
Friedman-Kien, Alvin E., 937
Frongillo, R. F., 22
Fu, Kwung P., 302, 414
Fujisawa-Kon, Noriko, 1070
Fujita, Norman K., 196
Fyfe, J. A. M., 1056

Galgiani, John N., 1073
Gallagher, James G., 193
Galuppo, L., 22
Gatner, E. M. S., 495
Gaunt, Howard, 786
Geiger, Robert H., 424
Gengo, Francis M., 836
Gentry, Layne, 139
Gentry, Layne O., 532
Georgopoulos, Apostolos, 386, 390
Gephart, Jeffrey F., 170
Geratz, J. D., 649
Gilbertson, John R., 917
Ginsburg, Charles M., 1086
Giordani, Bruno, 226
Girolami, Roland L., 454
Giron, Jose A., 279, 309
Glant, Michael D., 306
Glauser, Michel P., 381
Glew, Richard H., 930
Godfrey, Allan J., 705
Goldmann, Donald A., 294
Gordon, Jeffrey M., 867
Gordon, L. L., 1024
Gorman, W. G., 470
Govan, J. W. R., 1056
Grabow, G., 495
Gray, P. P., 209
Greaves, Wayne L., 253
Greenberg, Joseph, 346, 571
Greenwood, David, 66
Grey, Gloria, 513
Gruarin, Andrea, 675
Grundy, Scott M., 342
Gruninger, Robert P., 798
Guerrant, Richard L., 33
Guerriero, JoAnn C., 1089
Gurusiddaiah, S., 153
Gutmann, Laurent, 872
Guze, Lucien B., 179
Gwaltney, Jack M., Jr., 226

Haak, Willard J., 493
Hadley, W. Keith, 490
Haldane, E. Vanora, 51
Hall, Janet S., 620
Hall, Wendell H., 130
Hamilton-Miller, J. M. T., 1067
Hancock, Robert E. W., 777
Hansen, Sharon L., 335
Hansson, Hans B., 271
Harding, Alice L., 294
Harding, Godfrey K., 513
Hartman, Barry, 726
Hartmann, Manfred, 91
Harwood, Colin R., 540
Hashimoto, Hajime, 1070
Hayden, Frederick G., 226
Heinen, Ernst, 477
Hess, Georg, 44
Hewitt, William L., 196
Hill, Anita D., 424
Hill, Carter D., 190
Hintz, Marie, 608
Hirai, Keiji, 188
Hirschman, Shalom Z., 279, 309
Ho, Dah-Hsi, 1037
Ho, Dah-Hsi W., 139, 639
Hodge, Robert H., 33
Högenauer, Gregor, 260
Homberger, Françoise, 766
Horikoshi, Ann L., 144
Horne, Diane, 745
Hottendorf, G. H., 1004, 1024
Hufford, Charles D., 337
Humbert, G., 965

Ike, Yasuyoshi, 1032, 1070
Imanishi, Jiro, 922
Imkamp, F. M. G. H., 495
Inoue, Matsuhisa, 185, 188
Iravani, Abdollah, 598, 842
Irikura, Tsutomu, 188
Irvin, R. T., 1056
Ito, Akira, 188
Iwahi, Tomoyuki, 56

Jacks, Thomas M., 562
Javor, George T., 556
Jemsek, Joseph G., 532
Jenkin, Howard M., 238
Jenkins, Frank J., 365
Jensen, Karren K., 556
Johnson, David G., 1073
Jones, Brian M., 666
Jones, R. N., 122
Joseph, W. Patrick, 256
Juhlin, Ingmar, 271

Kabat, William J., 993
Kamimura, Toshiaki, 1013
Kaojarern, Sming, 736
Karmali, M. A., 593, 831
Kasik, J. E., 134
Katz, Ehud, 213

Kaye, Donald, 773
Kayser, Fritz H., 766
Keeney, Ronald E., 608
Kenny, Margaret A., 987
Kerr, Elizabeth A., 51
Kessler, Robert E., 39
Khan, Mohammed Y., 798
Kida, Makoto, 56
Kierulf, Peter, 82
Kilburn, James O., 346
Kim, Kwang Sik, 1075
King, Christine Y., 326
Kishida, Tsunataro, 922
Kizlaitis, Lilia R., 284
Klastersky, J., 72
Klayman, Daniel L., 682
Klein, Richard J., 937
Kleit, Stuart A., 575
Knox, John M., 117
Kobasa, William D., 773
Kobayashi, George S., 199
Kojo, Hitoshi, 393
Kok, S. K., 495
Kondo, Masahiro, 56
Kosaki, Goro, 397
Kotani, Shozo, 397
Koup, Jeffrey R., 323
Kreeft, John H., 253
Krongaard, Linda, 33
Kuck, Nydia A., 634
Kumano, Katsuhiko, 185
Kuramitsu, Sayoko, 519
Kusmiesz, Helen, 736
Kwan, Sallene, 958

Lam, Mildred, 461
Landesman, Sheldon H., 675, 794
Larsson, A., 927
Lauredo, Isabel, 826
LeBlanc, Barbara M., 1037
Lee, Francis H., 625
Lentino, Joseph R., 801
Lerner, A. Martin, 170
Leroy, A., 965
Ling, J., 8
Livingston, W. K., 114
Luft, Friedrich C., 306, 575
Lugo, Agripino, 352
Lunde, Per Knut M., 82
Lunke, Roger J., 851
Luper, W. E., 567

Macrina, Francis L., 997
Madden, Joseph A., 534
Madissoo, H., 1024
Madsen, Paul O., 443
Mahoney, David F., 934
Majer, Jaroslav, 628
Makover, S. Daniel, 584
Maksymiuk, Andrew W., 1037
Malewicz, Barbara, 238
Malke, Horst, 91
Manion, Carl V., 461
Margalith, Eva, 213

Markowitz, Sheldon M., 997
Marquis, Robert E., 807
Marrie, Thomas J., 51
Martin, R. F., 567
Martin, William J., 106
Maruyama, Hiromi B., 519
Mathewson, John J., 355
Matsen, John M., 450
Matsubara, Motoo, 922
Matsubara, Nobuyuki, 185
May, Richard S., 201
McChesney, James D., 337
McCracken, George H., Jr., 1086
McDonald, Peter J., 945
Medoff, Gerald, 199
Mejia, Proceso A., 290
Melick, Cheryl, 993
Merigan, Thomas C., 193
Meropol, Neal J., 414
Meyers, Burt R., 279, 309
Meyer zum Büschenfelde, Karl-Hermann, 44
Michalsen, Helge, 1029
Michel, M. F., 76
Mieth, Hubert, 386, 390
Mildener, Barry, 678
Miller, Brinton M., 562
Miller, Thomas E., 18
Mills, John, 256, 490
Minshew, Barbara H., 987
Mirtz, Lawrence, 332
Mirelli, Carlo, 508
Mirelman, David, 349, 687
Mitsuhashi, Susumu, 185, 188, 1032, 1070
Moellering, Robert C., Jr., 549, 789
Mok, Henry Y. I., 342
Mombelli, G., 72
Monaghan, Catriona, 266
Mong, Steven A., 575
Monick, M., 134
Moore, Evon, 801
Morales, Javier, 352
Moran, Elizabeth, 508
Moretti, A., 22
Motohashi, Kazuo, 1070
Mulder, Nanno H., 813
Murakami, Kazuhisa, 1
Murphy, Joanne C., 867
Musher, Daniel M., 117
Mychajlonka, Myron, 972

Nahmias, Andre J., 672
Nakao, Masafumi, 56, 901
Natelson, Ethan A., 532
Neirinck, L. G., 911
Nelson, John D., 736
Neu, Harold C., 298, 302, 414, 1013
Newman, Michael G., 144
Ng, W. S., 8, 12, 925
Nicas, Thalia I., 777
Nielsen, Ole S., 443
Nieweg, Hendrik O., 813
Nilsson-Ehle, Ingrid, 754
Nilsson-Ehle, Peter, 754
Nipper, Henry C., 620
Nishi, Takeshi, 56, 901
Nishida, Minoru, 393
Noji, Yumiko, 56
Nomura, Haruko, 922
Nord, Carl-Erik, 700
Nozaki, Yukimasa, 56
Nuchamowitz, Yael, 687

Öberg, B., 927
Oblack, Donna L., 106
Ogawa, Michio, 397
Ogilvie, Richard I., 253
Ohmae, Kenichi, 86
Oishi, John S., 1042
O'Leary, Dennis, 508
Onoe, Takatoshi, 487
Opfer, Bonnie J., 130
Opheim, Kent E., 323
Ormrod, Douglas J., 18
Østby, Nils, 82

Packer, R. R., 122
Pan, Theresa, 139
Pancic, F., 470
Pancorbo, Salvador, 605
Parker, Douglas S., 930
Parkhurst, J. Rodney, 881
Parsons, Janis, 218
Patamasucon, Pisespong, 736
Patapow, Alan, 205
Pavuk, Rosemary A., 930
Peterson, Lance R., 110
Petranyi, Gabor, 386, 390
Pfeffer, Morris, 1004
Phillips, Ian, 700
Phillips, L. E., 567
Plaut, Martin E., 147, 859
Pollard, Richard B., 193
Prior, Richard B., 359
Pruul, Hendrik, 945
Pulliam, Lynn, 490

Quinn, Richard P., 608

Rabin, Harvey R., 705
Raffle, Valerie J., 777
Ramírez-Ronda, Carlos H., 352
Ratcliff, Rodney M., 508
Ratzan, Kenneth R., 826
Reeves, D. S., 1064
Reichardt, Werner, 91
Reichenbach, Hans, 504
Reid, Robert A., 33
Reimer, Larry G., 1050
Reineke, Lester M., 493
Reller, L. Barth, 1050
Reynolds, Jack, 620
Richard, George A., 598, 842
Richards, Geoffrey K., 253
Richey, G. Dale, 312
Rissing, J. Peter, 218
Robertson, R. G., 668
Rogers, Alvin L., 1078
Rogers, T. E., 567
Ronald, Allan R., 513
Ronald, R. C., 153
Rosenberg, Eugene, 349
Rosenfeld, Mitchell B., 826
Rosenman, Sanford B., 545
Rotschafer, John, 740
Roush, David A., 355
Rubinstein, Ardon, 696
Rubinstein, Ethan, 687, 696
Ruf, Christine, 260
Russo, Mary E., 450
Rytel, Michael W., 801

Sagawa, Hirosuke, 487
Saida, Kiyoshi, 1032
Sande, Merle A., 613, 821
Sarosi, George A., 110
Savitch, Cary B., 256
Scammell, L. M., 1064
Scheld, W. Michael, 613, 821
Schentag, Jerome J., 147, 836, 859
Schinazi, Raymond F., 672
Schleupner, Charles J., 312
Schmidt, Friedrich, 371
Schoenknecht, Fritz D., 987
Schultz, William E., 545
Scott, Nigel W., 540
Shadomy, Smith, 201
Shaver, S. R., 649
Sheikh, Waheed, 429
Shigi, Yasutaka, 393
Shimi, Ibrahim R., 941
Shimizu, Shyoji, 1070
Shipkowitz, Nathan L., 454
Shipman, Charles, Jr., 682
Shuster, C. W., 328
Siddiqui, Yousuf, 798
Siebelist, JoAnn, 424
Sierra, Marcelino F., 794
Silva, Joseph, 980
Simard, Pierre, 101
Simpson, Margaret L., 798
Simpson, Russell B., 355
Sleijfer, Dirk T., 813
Sloan, Rebecca S., 306, 575
Smith, Arnold L., 294, 323
Smith, C. Jeff, 997
Smith, Sandra H., 682
Smyth, Robert D., 625, 1004
Snepar, Richard A., 773
Socransky, Sigmund S., 867
Söderholm, Jan, 700
Soll, David R., 1078
Solliday, JoAnne, 740
Solomon, David A., 534
Spector, Stephen A., 608
Spyker, Daniel A., 613, 821

Srinivasan, Subramaniam, 298, 302
Srulevitch, Elina, 279
Stamm, John M., 454
Stancato, F. A., 234
Standiford, Harold C., 620
Stanwick, Trevor L., 672
Steinberg, B. A., 470
Stephen, Edward L., 1042
Stratton, Charles W., 1050
Streker, R. G., 668
Suginaka, Hidekazu, 397, 487
Supapidhayakul, See-Ruern, 284
Suzue, Seigo, 188
Swantee, Carol A., 51
Swomley, Patricia, 335
Syriopoulou, Vassiliki P., 294

Takata, Naoki, 397
Takayama, Kuni, 346
Takeuchi, Mariko, 56
Tatem, Beverly, 620
Taylor, Diane E., 831
Taylor, Peter W., 786
Telep, Elizabeth, 584
Terakado, Nobuyuki, 86
Testa, Raymond T., 634
Thierbach, Georg, 504
Thomas, David Y., 952
Thompson, Marietta I. B., 450
Thomson, Margaret, 513
Thornsberry, C., 716
Thornsberry, Clyde, 122
Thys, J. P., 72
Tidwell, R. R., 649
Tierney, Una, 266
Timewell, Roger M., 700
Tofte, Robert W., 740
Toitou, Elka, 696
Tomasz, Alexander, 726, 745, 872
Toothaker, Roger D., 443
Tropp, Burton E., 678
Trottier, Sylvie, 761
Tsuchiya, Kanji, 56, 901
Turck, Marvin, 190
Turgeon, Pierre L., 645
Turner, J. R., 934

Umemoto, Toshio, 487
Unger, Frank M., 786
Ursing, Bo, 754

Vaara, Martti, 578
Vaara, Timo, 578
Van de Castle, Robert L., 226
van de Rijn, Ivo, 39
van der Waaij, Dirk, 813
Van Harken, Donald R., 625, 1004
van Leeuwen, W. B., 76
van Rensburg, A. J., 495
van Rensburg, C. E., 495
van Saene, Hendrik K. F., 813
van Treeck, Ulrich, 371
Venezia, R. A., 668
Verbist, Ludo, 222, 402, 407
Verhaegen, Jan, 222, 402
von Bergmann, Klaus, 342
Vu-Trong, K., 209

Wakasugi, Mamiko, 393
Walder, Mats, 271
Walker, Clay B., 867
Walter, Friedrich, 91
Wannemacher, Robert W., Jr., 1042
Washington, John A., II, 851
Watanabe, Junko, 519
Watanabe, Kimihiro, 519
Watanakunakorn, Chatrchai, 1089
Weaver, Susanne S., 639
Weber, Allan F., 323
Welling, Peter G., 443
Welter, C. Joseph, 562
Wennersten, Christine, 549
Wetherall, Bruce L., 945
Whelan, William L., 1078
White, John D., 917
White, L. O., 1064
White, Robyn, 508
Wiedemann, Bernd, 371
Wigdahl, Brian L., 881
Wigren, David I., 798
Williamson, Russell, 872
Wills, P. J., 526
Wilson, Kenneth H., 980
Wise, R., 526
Wolfe, A. D., 234
Won, Chen-Jeu, 922
Wood, Sheila J., 33
Woodley, Charles L., 571
Wright, N., 526
Wright, Rosemary, 584

Yangco, Bienvenido G., 534
Yogev, Ram, 545, 993
Yonezawa, Shoichi, 86
Yoshida, Tadashi, 1
Yotsuji, Akira, 185

Zafriri, Dina, 349
Zubair, M. Uppal, 29
Zweighaft, Teresa C., 1086

SUBJECT INDEX

VOLUME 19

2-Acetylpyridine thiosemicarbazones
  herpes simplex virus inhibition, 682
Acetyltransferase assay
  serum aminoglycosides, compared, 1064
Acycloguanosine
  herpesvirus DNA inhibition, 927
Acyclovir
  antiviral effect, combined with interferon, 672
  latent herpes simplex virus in mouse trigeminal ganglia, 937
  single-dose pharmacokinetics, 608
Adenosine 3′,5′-monophosphate system
  deficient *E. coli* mutants resistant to mecillinam, 540
Adenylate cyclase
  deficient *E. coli* mutants resistant to mecillinam, 540
Aerobic bacteria
  new cephalosporins, activity, 490
Aeromonas hydrophila
  in vitro susceptibilities to 32 drugs, 357
Agar plate dilution susceptibility testing
  moxalactam, 130
Alcohols
  long-chain, mycoplasma inhibition, 917
AM-715
  systemic infections in mice, 188
  urinary tract infections in mice, 188
Amantadine hydrochloride
  toxicity in healthy adults, compared, 226
Amidines
  inhibition of respiratory syncytial virus-host cell interactions, 649
Amikacin
  anti-*Pseudomonas* activity, 72
  critically ill patients
    accumulation pharmacokinetics, 147
  in patients' bronchial secretions, 72
  intestinal absorption in rats, 696
  nephrotoxicity, 147
  synergy with penicillin, *S. faecalis* resistance, 549
Amikacin sulfate
  levels in human serum and bile, 352
Aminocyclitol
  A. aureus resistance, genetic analysis, 766
Aminoglycoside assay
  serum: effect of cefamandole, cefoxitin, 567
Aminoglycoside resistance
  P. aeruginosa mutants, 958
Aminoglycosides
  accumulation in rat kidneys, 381
  nephrotoxic dose responses in rats, 1024
  pyelonephritis prevention in rats, 381
Amoxicillin
  pharmacokinetics in infants compared with cyclacillin, 1086
  synergy with clavulanic acid vs. *H. influenzae*, 993
Amphotericin B
  antifungal activity, 106
  candidiasis in rabbits, 179
  methyl ester derivatives, antifungal activity, 106
  neutrophil stimulation in humans and dogs, 284
  plus rifampin vs. *C. neoformans*, 196
Ampicillin
  experimental listeriosis in nude mice, 76
  experimental *S. typhimurium* infection, 328
  intrarenal distribution in pyelonephritic rats, 761
  with moxalactam or cefotaxime vs. group B streptococci, 794
Anaerobic bacteria
  ionophores, compared, 519
  susceptibility to nine antibacterial agents, 51
Antibiotic TA
  M. xanthus, mode of action, 349
Antiseptics
  neutralizer for evaluation, 429
Apalcillin
  S. marcescens, 397
9-β-D-Arabinofuranosyladenine
  hepatitis B virus DNA inhibition, 44
  5′-triphosphate, 44
1-β-D-Arabinofuranosylcytosine
  hepatitis B virus DNA inhibition, 44
  5′-triphosphate, 44
Arabinosyladenine
  effects against viruses, 170
Arabinosyladenine 5′-monophosphate
  effects against viruses, 170
Arabinosylhypoxanthine
  effects against viruses, 170
Assay
  enzymatic and liquid chromatographic, for chloramphenicol, 323

Bacillus subtilis
  synergism of weak acids and alcohols, 1082
BACTEC 460
  serum aminoglycoside assay
    cefamandole effects, 567
    cefoxitin effects, 567
Bacterial infections
  moxalactam therapy, 740
Bacteroides fragilis
  beta-lactamase in resistance to beta-lactams, 248
  moxalactam, 248
  N-formimidoyl thienamycin, 248
Bacteroides fragilis group
  erythromycin susceptibility
    carbon dioxide, effects, 335
    pH, effects, 335
Bacteroides melaninogenicus group
  β-lactamases, isoelectric focusing, 700
Benzimidazole
  antibacterial, antifungal activities of derivatives, 29
Benzoxazole
  antibacterial, antifungal activities of derivatives, 29

Benzylpenicillin
S. marcescens, resistance, 397
Beta-lactam antibiotics
antibacterial effects of combinations, 634
E. coli susceptibility during rod-to-sphere transition, 891
susceptibility of multiply resistant pneumococci, 675
tolerance screening in *N. gonorrhoeae*, 645
BHK-21 cells
repair of polyene-induced membrane alterations, 238
Bile
amikacin sulfate levels in humans, 352
Biliary excretion
piperacillin in cholecystectomy patients, 309
Biliary lipids
rifampin effects in humans, 342
Bronchial secretions
amikacin in, 72
tobramycin in, 72

Cairomycins A and C
isolation, purification, characterization, 941
Streptomyces sp. strain AS-C-19, 941
Campylobacter jejuni
resistance patterns in Canada, 593
transmissible tetracycline resistance plasmids, 831
Candida albicans
5-fluorocytosine-resistant variants, 1078
increase after nontoxic polyene treatment, 199
Candidiasis
amphotericin B in rabbits, 179
Capnocytophaga
antimicrobial susceptibility, 144
Carbadox
R plasmid in porcine *E. coli*, 86
Carbenicillin
synergy with tobramycin, 332
Cefamandole
effects on BACTEC serum aminoglycoside assay, 567
H. influenzae, 101
pharmacokinetics, 298
osseous tissue, 851
tissue distribution in rats, 625
Cefazolin
effects on *K. pnuemoniae* morphology, 901
pharmacokinetics, 302
compared with moxalactam, 613
S. marcescens, 397
tissue distribution in rats, 625
Cefmenoxime
antibacterial activity in vitro, in vivo, 56
antimicrobial activity, 454
Cefoperazone
experimental endocarditis in rabbits, 773
pharmacokinetics, 296
dialysis, 821
normal volunteers, 821
patients with neoplastic diseases, 1037
renal insufficiency, 821
synergy with tobramycin, 332
Ceforanide
endocarditis, staphylococcal and streptococcal, 256
tissue distribution in rats, 625
Cefotaxime
extravascular passage in humans, 22
gonorrhea treatment, 798
group B streptococci
activity alone, 794
combined with ampicillin or penicillin, 794
pharmacology in renal and hepatic disease, 526
synergy with tobramycin, 332
Cefotiam
effects on *K. pneumoniae* morphology, 901
Cefoxitin
chemoprophylaxis in orthopedic surgery, 826
disposition during peritoneal dialysis, 253
effect on BACTEC serum aminoglycoside assay, 567
M. fortuitum susceptibility in vitro, 205
nephrotoxicity in experimental renal failure, 18
Ceftazidime
activity against nosocomial pathogens, 1067
Ceftizoxime
compared with its stereoisomer
antibacterial activity, 393
penicillin-binding proteins, affinity, 393
S. marcescens, 397
Ceftriaxone
antibacterial activity, 414
Cefuroxime
pharmacokinetic assays, 443
pharmacokinetics in renal function, 443
Cephalosporinase
from *P. vulgaris*, 185
Cephalosporins
hamster colitis model for evaluation, 980
β-lactamase stable, vs. β-lactamase producers, 407
third generation, vs. aerobes, 490
Cephalothin
chemoprophylaxis in orthopedic surgery, 826
Cephamycin C
induced swine salmonellosis, 562
Cetomacrogol
intestinal aminoglycoside absorption in rats, 696
nonionic surfactant in intestinal drug absorption, 696
Chemoprophylaxis
cefoxitin, cephalothin in orthopedic surgery, 826
Chloramphenicol
E. coli susceptibility to human leukocytes, enhanced, 945
enzymatic vs. liquid chromatographic assay, 323
fluorinated analogs, activity, 294
Chloroquine
P. berghei receptor, sequestration, 589
Cholecystectomy
biliary excretion of piperacillin, 309
Cholestyramine
in vitro interaction with vancomycin, 326
Chromatography
reverse-phase, high-pressure liquid, of ketoconazole, 110
Clavulanic acid
synergy with amoxicillin vs. *H. influenzae*, 993
Clindamycin
gingival crevicular fluid and serum levels, 867
Clinical specimens
veterinary, resistant *S. krefeld* in, 355

Clostridium difficile
transferable tetracycline resistance, 997
Clostridium perfringens
macrolide-lincosamide-streptogramin resistance patterns, 274
penicillin resistance, 51
CP-45,899
inconsistent synergy with β-lactams, 361
Cryptococcus neoformans
amphotericin B-rifampin, in vitro, 196
Cyclacillin
pharmacokinetics in infants compared with amoxicillin, 1086
Cystic fibrosis
modified penicillin-binding proteins during treatment, 705
netilmicin pharmacokinetics, 1029
P. aeruginosa mucoid strains, drug resistance, 1056
Cytomegalovirus
arabinosyladenine and antivirals, effects, 170
Cytospora
grahamimycins, 153

Dapsone
effects on human neutrophils and lymphocytes, 495
lepromatous leprosy, 495
Deoxyribonucleic acid
herpesvirus, inhibited, 927
Deoxythymidine kinase
trifluorothymidine in mouse cell inhibition, 881
Desacetyl cefotaxime
pharmacology in renal and hepatic disease, 526
Dibekacin
aerobic bacteria, 490
compared in vitro with gentamicin, 190
Dictyostelium discoideum
RNA synthesis inhibited by nogalamycin, 657
2′,3′-Dideoxyadenosine
antibacterial activity, 424
Disk diffusion susceptibility testing
moxalactam, 130
Distribution
methicillin
extravascular fluid, 836
heart valves, 836
serum, 836
Dogs
antibiotic resistance in fecal coliform flora, 266

(*E*)-5-(2-Bromovinyl)-2′-deoxyuridine
herpesvirus DNA inhibition, 927
Ectromelia virus
protection of mice by mouse interferon, 922
Endocarditis
cefoperazone treatment in rabbits, 773
ceforanide therapy of staphlococcal and streptococcal, 256
Enterobacteria
Ro 13-9904 activity, 66
Enterococci
susceptibility to *N*-formimidoyl thienamycin, 789
Enzyme-mediated immunoassay
serum aminoglycosides, compared, 1064
Erythromycin
B. fragilis group susceptibility
carbon dioxide, effects, 335
pH, effects, 335
resistance induced in *S. aureus* by metabolite, 628
Erythromycin estolate
pharmacokinetics in young infants, 736
Erythromycin ethylsuccinate
pharmacokinetics in young infants, 736
Escherichia coli
adenylate cyclase-deficient mutants resistant to mecillinam, 540
ampicillin resistance transposon, 371
carbadox resistance plasmid, in pigs, 86
chloramphenicol enhancement of susceptibility, 945
control strain, standard susceptibilities, 1050
drug resistant, in Japanese pigs and pig handlers, 1032
effects of new thiosemicarbazone, H, 234
enterotoxigenic, antibiotic effects on, 290
glycerol 3-phosphate halo analogs, 678
inhibition by thioglycerol, 556
interaction with haemocin, 668
interaction with nifurzide, 477
permeability, susceptibility to β-lactams, 369
rod-to-sphere transition and susceptibility, 891
R plasmids from Japanese strains, 1070
R plasmids in Japanese pigs and pig handlers, 1032
sensitization to human serum by mecillinam, 786
streptomycin, sulfonamide resistance plasmid, 371
susceptibility to human leukocytes, 945
tiamulin, ribosomal binding region, 260
Ethambutol
effects on *M. smegmatis* phospholipids, 346

Fecal coliforms
antibiotic resistance in flora of dogs, 266
Fecal flora
sulfamethoxazole-trimethoprim and trimethoprim resistance, 33
Fluoride
effect on *S. aureus* proton barrier, 807
5-Fluorocytosine
C. albicans, resistant variants, 1078
Fluoroimmunoassay
serum aminoglycosides, compared, 1064
2′-Fluoro-5-iodo-aracytosine
herpesvirus DNA inhibition, 927
Fortimicin A
antibacterial activity compared, 122
FR-31564
activity in vitro and in vivo
comparative, 1013
enhancement, 1013
Fusobacterium nucleatum
filament formation induced by mecillinam, 487

Gamma-aminobutyric acid
S. lincolnensis, 493
Gardnerella vaginalis
susceptible to high-level sulfonamides, 666
Gentamicin
compared in vitro with dibekacin, 190
critically ill patients
accumulation pharmacokinetics, 147

E. coli R plasmids in Japan, 1070
intestinal absorption in rats, 696
latex agglutination inhibition card test, compared, 620
latex agglutination inhibition card test, 930
nephrotoxicity, 147, 859
P. aeruginosa susceptibility testing
calcium and magnesium effects on results, 987
Mueller-Hinton agar, 987
P. auerginosa outer membrane protein in resistance, 777
peritoneal fluid concentrations in peritonitis, 312
pharmacokinetics
continuous ambulatory peritoneal dialysis, 605
radioimmunoassay, compared, 620
serum assay methods compared, 508
Glycerol 3-phosphate
halo analogs vs. *E. coli*, 678
Gonorrhea
cefotaxime vs. penicillin treatment, 798
Grahamimycins
Cytospora sp. Ehrenb. W.F.P.L. 13A, 153
Gram-negative bacilli
meningitis, moxalactam treatment, 218
Granulocytopenic patients
digestive tract decontamination to prevent infections, 813
Group A streptococci
lipoteichoic acid release, 39
penicillin-binding proteins, 872
penicillin effects, 39
susceptibility studies, 716
synergy, 716
Group B streptococci
moxalactam, cefotaxime with/without ampicillin, penicillin, 794
penicillin-treated, susceptibility, 745
susceptibility studies, 716
susceptibility to human polymorphonuclear leukocytes, 745
synergy, 716
Gynecomastia
ketoconazole side effect, 1073

Haemocin
interaction with *E. coli*, 668
Haemophilus influenzae
beta-lactamase producing vs. cefamandole, 101
non-beta-lactamase producing vs. cefamandole, 101
penicillin-binding proteins, 584
Ro 13-9904 susceptibility, 925
Haemophilus influenzae type b
amoxicillin-clavulanic acid synergy, 993
Hamster colitis model
cephalosporins evaluated, 980
Heart valves
methicillin distribution, 836
Hemodialysis
moxalactam pharmacokinetics, 575
piperacillin pharmacokinetics, 279
Hepatic failure
cefotaxime pharmacology, 526
Hepatitis B virus
9-β-D-arabinofuranosyladenine effects, 44
1-β-D-arabinofuranosylcytosine effects, 44
DNA polymerase inhibition, 44
Herpes simplex virus
2-acetylpyridine thiosemicarbazones, 682
acyclovir, 937
arabinosyladenine and antivirals, effects, 170
combined effects of interferon and acyclovir, 672
mouse trigeminal ganglia, acyclovir treatment, 937
protection of mice by mouse interferon, 922
Win 41258-3 activity in animal infection, 470
Herpesvirus
DNA synthesis inhibition, 927
Herpes zoster
interferon treatment, in cancer patients, 193
Human interferon
antiviral effect, combined with acyclovir, 672
Human leukocytes
E. coli susceptibility enhanced, 945
Human polymorphonuclear leukocytes
susceptibility of group B streptococci, 745
Human serum
E. coli sensitization by subinhibitory mecillinam, 786

Immune response, impaired
ampicillin versus listeriosis in nude mice, 76
Infants
pharmacokinetics of cyclacillin and amoxicillin, 1086
Infection prevention
digestive tract decontamination, 813
Influenza virus
ribavirin inhibition in MDCK cells, 712
Interferon
ectromelia virus protection in rats, 922
herpes simplex virus protection in mice, 922
mouse, protection of mice from virus, 922
Interferon, human leukocyte
herpes zoster in cancer patients, 193
Ionophores
activity vs. anaerobes, compared, 519
effect on *S. mutans* proton barrier, 807

Ketoconazole
gynecomastia, 1073
liquid chromatographic assay, 110
Klebsiella pneumoniae
morphological effects of cefotiam, transition, 901

β-Lactam antibiotics
E. coli permeability, susceptibility, 369
effects on peptidoglycan in *P. aeruginosa*, 687
inconsistent synergy with CP-45,899, 361
resistant *P. aeruginosa* in cystic fibrosis, 705
S. marcescens resistances compared, 397
β-Lactamase
stability of moxalactam, 1
stable cephalosporins vs. producers, 407
β-Lactamases
isoelectric focusing in *B. melaninogenicus*, 700
Latex agglutination inhibition card test
gentamicin assay, evaluation, 620
serum gentamicin, 930
Lepromatous leprosy

dapsone and polymorphonuclear leukocytes, 495
Lincomycin
S. pyogenes resistance, genetics, 91
zonal resistance, genetics, 91
Listeria monocytogenes
susceptibility to *N*-formimidoyl thienamycin, 789
Listeriosis
ampicillin, in nude mice, 76
Long-chain alcohols
mycoplasma inactivation, 917
Lower respiratory tract infections
moxalactam therapy, 801

Macrolide-lincosamide-streptogramin antibiotics
resistance patterns in animal *C. perfringens*, 274
Mecillinam
E. coli adenylate cyclase-deficient mutants, 540
E. coli sensitization to human serum, 786
experimental *S. typhimurium* infection, 328
F. nucleatum filament formation, 487
Meningitis
gram-negative bacilli, moxalactam treatment, 218
Methicillin
bacterial growth phase and susceptibility, 1075
distribution in rabbit heart valves, 836
S. aureus penicillin-binding proteins, 726
6′-*N*-Methylamikacin
S. faecalis, 549
N-Methylcolchiceinamide
metabolites, 465
microbial transformations, 465
Metronidazole
metabolism in humans, 754
pharmacokinetics in humans, 754
Mezlocillin
single-disk agar diffusion susceptibility test, 359
Minimal bactericidal concentrations
effect of bacterial growth phase, 1075
Minimal inhibitory concentrations
effect of bacterial growth phase, 1075
Minimum inhibitory concentrations
standards, in Mueller-Hinton broth, 1050
MK0787
in vitro against resistant isolates, 114
in vitro study, 201
Morphology
cephalosporins, effects on *K. pneumoniae*, 901
penicillin G, effects on *N. meningitidis*, 901
Moxalactam
bacterial infection therapy, 740
beta-lactamase resistance in *B. fragilis*, 248
B. fragilis, in vitro, 248
group B streptococci
alone, 794
combined with ampicillin or penicillin, 794
β-lactamase stability, 1
β-lactamase substrate, 934
lower respiratory tract infections, 801
meningitis due to gram-negative bacilli, 218
7α-methoxy group in β-lactamase stability, 1
pharmacokinetics
compared with cefazolin, 613
compared with cephalosporins, 302
during hemodialysis, 575
impaired renal function, 965
normal renal function, 965
renal insufficiency, 461
pharmacology in cancer patients, 639
1-sulfur congener, 1
susceptibility tests, 130
synergy with tobramycin, 332
Mueller-Hinton agar
susceptibility testing, performance predictability, 987
Mueller-Hinton broth
standard drug susceptibilities of control bacteria, 1050
Murein
synthesis in *E. coli* rod-to-sphere transition, 891
Mutacin GS-5
S. pyogenes, loss of susceptibility, 166
Mycobacterium avium-intracellulare
rapid radiometric susceptibility assay, 534
Mycobacterium fortuitum
cefoxitin susceptibility in vitro, 205
Mycobacterium smegmatis
auxotrophic mutants, 571
ethambutol effects on phospholipid metabolism, 346
vancomycin isolation of specific auxotrophs, 571
Mycoplasma
inactivation by long-chain alcohols, 917
Myxococcus xanthus
antibiotic TA, mode of action, 349
Myxothiazol
antifungal, 504
respiration interference, 504

Nafcillin
penetrance into human ventricular fluid, 545
Naftifine
in vitro activity, 386
in vivo activity, 390
Nalidixic acid
systemic infections in mice, 188
trimethoprim/sulfamethoxazole compared in urinary tract infections, 598
urinary tract infections in mice, 188
Neisseria gonorrhoeae
Hong Kong isolates, susceptibility, 12
penicillinase-producing, in Canada, 952
penicillin-binding proteins, properties, 316
Ro 13-9904 susceptibility, 925
screening for tolerance to beta-lactams, 645
Neisseria meningitidis
morphology, effects of subinhibitory penicillin G, 911
Neoplastic diseases
cefoperazone pharmacokinetics, 1037
Nephrotoxicity
aminoglycoside dose responses in rats, 1024
cefoxitin in rats with renal failure, 18
critically ill patients
amikacin, 147
gentamicin, 147
gentamicin, tobramycin compared, 859
vancomycin in rats, 306
Netilmicin
nephrotoxic dose responses in rats, 1024

pharmacokinetics in cystic fibrosis patients, 1029
Neutrophils
amphotericin B stimulation, 284
N-Formimidoyl thienamycin
in vitro study, 201
alone or in combination with aminoglycoside, 789
beta-lactamase resistance in *B. fragilis*, 248
B. fragilis, in vitro, 248
enterococci, susceptibility, 789
in vitro activity compared, 402
in vitro against resistant isolates, 114
L. monocytogenes, susceptibility, 789
Nifurzide
antiinfectious agent, 477
interaction with *E. coli*, 477
Nogalamycin
RNA synthesis inhibited in *D. discoideum*, 657
Nosocomial pathogens
ceftazidime activity, 1067

Orthopedic surgery
chemoprophylaxis with cefoxitin, cephalothin, 826
Osseous tissue
cefamandole pharmacokinetics, 851

Parainfluenza virus
ribavirin inhibition in MDCK cells, 712
Penicillin
bacterial growth phase and susceptibility, 1075
C. perfringens decreased susceptibility, 51
effects on group A *Streptococcus*, 39
gonorrhea treatment, compared with cefotaxime, 798
synergy with amikacin, *S. faecalis* resistance, 549
treated group B streptococci, susceptibility to serum, 745
with moxalactam or cefotaxime vs. group B streptococci, 794
Penicillinase
N. gonorrhoeae producers in Canada, 952
Penicillin-binding proteins
altered, in methicillin-resistant *S. aureus*, 726
group A streptococci, characterized, 872
H. influenzae, 584
N. gonorrhoeae, properties, 316
P. aeruginosa, changes during β-lactam treatment, 705
Penicillin G
effects on tolerant *S. mutans* strain, 972
N. meningitidis morphology, 911
Peptidoglycan
β-lactam effects on synthesis in *P. aeruginosa*, 687
Periodontal bacteria
clindamycin, gingival crevicular fluid levels, 867
Peritoneal dialysis
cefoxitin disposition, 253
continuous ambulatory, gentamicin pharmacokinetics, 605
Peritonitis, spontaneous bacterial
gentamicin in peritoneal fluid, 312
Pharmacokinetics
acyclovir
single-dose, 608
amikacin
critically ill patients, 147
amoxicillin in infants, 1086
cefamandole, 298
cefamandole in osseous tissue, 851
cefazolin, 302
cefoperazone, 298
dialysis, 821
normal volunteers, 821
renal insufficiency, 821
cefoperazone in patients with neoplastic diseases, 1037
cefoxitin
during peritoneal dialysis, 253
cefuroxime
assays for, 443
impaired renal function, 443
cyclacillin in infants, 1086
erythromycin estolate and ethylsuccinate, in infants, 736
gentamicin
continuous ambulatory peritoneal dialysis, 605
critically ill patients, 147
metronidazole and tinidazole in humans, 754
moxalactam, 302
cefazolin, compared, 613
during hemodialysis, 575
impaired renal function, 965
normal renal function, 965
renal insufficiency, 461
netilmicin in cystic fibrosis patients, 1029
piperacillin
chronic renal failure, 450
hemodialysis, 279
patients with moderate renal failure, 279
Pharmacology
cefotaxime in renal and hepatic disease, 526
moxalactam in cancer patients, 639
Phospholipids
ethambutol effects on *M. smegmatis* metabolism, 346
Pigs
cephamycin C in salmonellosis, 562
E. coli R plasmids in Japan, 1032
Pipemidic acid
systemic infections in mice, 188
urinary tract infections in mice, 188
Piperacillin
biliary excretion in cholecystectomies, 309
effects on platelet function in normal humans, 532
hemodialysis, 279
pharmacokinetics
chronic renal failure, 450
patients with moderate renal failure, 279
Plasmids
transmissible, from *C. jejuni*, 831
Plasmodium berghei
chloroquine receptor, sequestration, 589
Platelets
piperacillin effects on function, 532
Pneumonia
moxalactam therapy, 801
Polyene antibiotics
nontoxic concentrations, effects on *C. albicans*, 199
Polyene macrolide antibiotics

membrane alteraton repair in BHK-21 cells, 238
Polymorphonuclear leukocytes
dapsone effects on function, 495
Polymyxin
S. typhimurium permeability barrier disruption, 578
Primaquine
metabolism, 337
Proteus vulgaris
cephalosporinase, some properties, 185
Pseudomonas aeruginosa
activity of amikacin or tobramycin in bronchial secretions, 72
aminoglycoside-resistant mutants, 958
control strain, standard drug susceptibilities, 1050
gentamicin susceptibility testing
calcium and magnesium effects on results, 987
Mueller-Hinton agar, 987
β-lactam effects on peptidoglycan synthesis, 687
mucoid strains in cystic fibrosis
antibiotic resistance, 1056
outer membrane proteins, 1056
outer membrane protein in susceptibility
gentamicin, 777
streptomycin, 777
penicillin-binding proteins
β-lactam-resistant, 705
modified during cystic fibrosis treatment, 705
tobramycin synergy with other drugs, 332
Pyelonephritis
intrarenal ampicillin distribution in rats, 761
prevention in rats by aminoglycosides, 381

Rabbits
rosaramicin phosphate in experimental syphilis, 117
Radioimmunoassay
serum aminoglycosides, compared, 1064
vancomycin, 139
Radiometric method, rapid
M. avium-intracellulare susceptibility, 534
Rats
aminoglycoside nephrotoxic dose responses, 1024
tissue distribution of cephalosporins, 625
Renal failure
cefotaxime pharmacology, 526
Renal function
moxalactam pharmacokinetics, 965
Renal insufficiency
cefoperazone pharmacokinetics, 821
Repair
polyene-induced membrane alterations in BHK-21 cells, 238
Resistance
gentamicin, R plasmids in *E. coli* in Japan, 1070
tetracycline, in *C. difficile*, transferable, 997
Resistance plasmid
streptomycin, sulfonamide, in *E. coli*, 371
Respiration, yeast cell
myxothiazol interference, 504
Respiratory syncytial virus
cell fusion blocked by amidines, 649
Ribavirin
antimyxovirus activity, 712
distribution in rats and monkeys, 1042
effect on Rous sarcoma virus transformation, 364
influenza, parainfluenza virus inhibition, 712
Ribonucleic acid
D. discoideum, synthesis inhibited by nogalamycin, 657
synthesis inhibition by thiosemicarbazone H in *E. coli*, 234
Rifampin
action with vancomycin vs. *S. aureus*, 1089
biliary lipids, human, effects, 342
plus amphotericin B vs. *C. neoformans*, 196
Rifamycins
antibacterial effects, 134
immunosuppressive effects, 134
Rimantadine hydrochloride
toxicity in healthy adults, compared, 226
Ro 13-9904
activity against dense enterobacteria, 66
comparative studies, 435
H. influenzae, *N. gonorrhoeae* susceptibility, 925
in vitro activity, 222
susceptibility of Hong Kong salmonellae, 8
Rosaramicin
susceptibility of multiply resistant pneumococci, 675
Rosaramicin phosphate
experimental syphilis in rabbits, 117
Rous sarcoma virus
effect of ribavirin, 364
R plasmids
carbadox resistance, in porcine *E. coli*, 86
E. coli in Japanese pigs and pig handlers, 1032
gentamicin-resistant *E. coli* in Japan, 1070
lincomycin zonal resistance, in *S. pyogenes*, 91

Salmonella cholerae-suis
cephamycin C in pigs, 562
Salmonella krefeld
antibiotic resistant, in clinical veterinary specimens, 355
Salmonella spp.
Hong Kong isolates, susceptibility, 8
Ro 13-9904 susceptibility, 8
susceptibility to various agents, 8
Salmonella typhimurium
ampicillin, mecillinam treatment of experimental infection, 328
permeability barrier disruption by polymyxin, 578
Sarmoxicillin
absorption, distribution, metabolism, 1004
amoxicillin prodrug, 1004
SCE-1365
antimicrobial activity, 454
Serratia marcescens
β-lactam resistance, 397
Serum
gentamicin assay methods compared, 508
gentamicin levels by latex agglutination inhibition card test, 930
tobramycin assay, 934
Serum, human
amikacin sulfate levels, 352
Serum aminoglycosides
assay methods compared, 1064
enzyme-mediated immunoassay, 1064
Shigella isolates

susceptibility, 271
Single-disk agar diffusion test
mezlocillin susceptibility, 359
Skin blister
sulfonamides and trimethoprim in fluid, 82
Skin chamber technique
cefotaxime extravascular passage in humans, 22
Skin window technique
cefotaxime extravascular passage in humans, 22
Staphylococcus aureus
aminocyclitol resistance, genetic analysis, 766
control strain, standard drug susceptibilities, 1050
erythromycin resistance induced, 628
penicillin-binding proteins in methicillin-resistant strains, 726
rifampin action with vancomycin, 1089
vancomycin action with rifampin, 1089
Streptococcus faecalis
plasmid-mediated, aminoglycoside-modifying enzymes, 549
resistance to penicillin-aminoglycoside synergy, 549
Streptococcus mutans
effects of low penicillin on tolerant strain, 972
proton conductance
fluoride effects, 807
ionophores effects, 807
Streptococcus pyogenes
genetics, 91
lincomycin zonal resistance, plasmid associated, 91
mutacin GS-5, mutational loss of susceptibility, 166
Streptomyces fradiae
phosphate control of tylosin biosynthesis, 209
tylosin-producing, metabolic regulation, 209
Streptomyces lincolnensis
gamma-aminobutyric acid, 493
Streptomyces sp. strain AS-C-19
cairomycins A, B, and C, 941
Streptomycin
P. aeruginosa outer membrane protein in resistance, 777
Suction skin blister technique
cefotaxime extravascular passage in humans, 22
Sulfamethoxazole-trimethoprim
resistance among patients' fecal flora, 33
Sulfisoxazole
trimethoprim vs. urinary tract infections, compared, 842
Sulfonamides
concentrations in human skin blister fluid and serum, 82
G. vaginalis susceptibility, 666
penetration, 82
Synergism
amoxicillin-clavulanic acid vs. *H. influenzae* type b, 993
weak acids and alcohols vs. *B. subtilis*, 1082
Synergy
amphotericin B-rifampin vs. *C. neoformans*, 196
CP-45,899–β-lactam antibiotics, inconsistent, 361
penicillin-amikacin, *S. faecalis* resistance, 549
tobramycin-other drugs vs. *P. aeruginosa*, 332
Syphilis
rosaramicin phosphate in rabbits, 117

Tetracycline
transferable resistance in *C. difficile*, 997
transmissible resistance plasmids in *C. jejuni*, 831
Thiamphenicol
fluorinated analogs, activity, 294
Thioglycerol
E. coli inhibition, 556
Thiosemicarbazone H
antibacterial, 234
antiparasitic, 234
effects on *E. coli*, 234
Tiamulin
ribosomal binding region in *E. coli*, 260
Tinidazole
metabolism in humans, 754
pharmacokinetics in humans, 754
Tobramycin
anti-*Pseudomonas* activity, 72
assay in serum containing moxalactam, 934
in patients' bronchial secretions, 72
nephrotoxicity, 859
synergy against *P. aeruginosa*, 332
Toxicity
amantadine hydrochloride, healthy adults, 226
rimantadine hydrochloride, healthy adults, 226
Trifluorothymidine
deoxythymidine kinase in mouse cell inhibition, 881
mouse cell replication inhibition, 881
Trigeminal ganglia, mouse
acyclovir for latent herpes simplex virus, 937
Trimethoprim
concentrations in human skin blister fluid and serum, 82
penetration, 82
resistance among patients' fecal flora, 33
sulfisoxazole vs. urinary tract infections, compared, 842
Trimethoprim-rifampin
localized urinary infection, 513
Trimethoprim/sulfamethoxazole
nalidixic acid compared in urinary tract infections, 598
Tylosin
phosphate control of biosynthesis in *S. fradiae*, 209

Urinary tract infections
AM-715, in mice, 188
nalidixic acid, in mice, 188
nalidixic acid vs. trimethoprim/sulfamethoxazole, 598
pipemidic acid, in mice, 188
trimethoprim-rifampin, 513
trimethoprim vs. sulfisoxazole, 842

Vaccinia virus
zinc chloride inhibition of maturation, 213
Vancomycin
action with rifampin vs. *S. aureus*, 1089
enrichment for *M. smegmatis* auxotrophic mutants, 571
in vitro interaction with cholestyramine, 326
nephrotoxicity in rats, 306
radioimmunoassay, 139
Varicella-zoster virus
arabinosyladenine and antivirals, effects, 170

Ventricular fluid
nafcillin penetrance in hydrocephalic children, 545

Win 41258-3
activity vs. herpes simplex virus in animals, 470

Yeasts
amphotericin B susceptibility, 106

Zinc chloride
inhibition of vaccinia virus maturation, 213

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
January	31 January 1981	1–208
February	9 March 1981	209–370
March	28 March 1981	371–493
April	30 April 1981	495–685
May	8 June 1981	687–940
June	18 June 1981	941–1091

ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 19

WASHINGTON, DC 20006

1981

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 19 • 1981

EDITORIAL BOARD

Leon H. Schmidt, *Editor-in-Chief* (1985)
University of Alabama in Birmingham, Birmingham, Alabama

Herbert I. Ennis, *Editor* (1982)
Roche Institute of Molecular Biology, Nutley, New Jersey

Joel G. Flaks, *Editor* (1981)
University of Pennsylvania, Philadelphia

Robert L. Hamill, *Editor* (1985)
Eli Lilly & Company, Inc. Indianapolis, Indiana

Edward W. Hook, *Editor* (1981)
University of Virginia, Charlottesville

George A. Jacoby, Jr., *Editor* (1985)
Massachusetts General Hospital Boston, Massachusetts

Norris Allen (1983)
Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1983)
George R. Aronoff (1983)
Robert Austrian (1983)
Arthur L. Barry (1983)
John E. Bennett (1981)
Gerald P. Bodey (1983)
Robert E. Brummett (1982)
Lawrence E. Bryan (1982)
D. Buyske (1983)
C. Glenn Cobbs (1983)
Paul S. Cohen (1983)
Nigel A. C. Curtis (1983)
Naomi Datta (1981)
Lawrence E. Day (1983)
R. Gordon Douglas, Jr. (1983)
Theodore Eickhoff (1982)
Arthur English (1983)
David S. Feingold (1981)
Robert Fekety (1981)
Sydney Finegold (1982)
Robert J. Fitzgerald (1983)
Martin Forbes (1983)
Anthony J. Glazko (1981)
Irving H. Goldberg (1982)
Harry Gooder (1982)
Jack Gwaltney (1983)
Wendell H. Hall (1983)
Maurice W. Harmon (1981)
Michael Higgins (1983)
Ronald D. Hinsdill (1982)
Dah Hsi Wang Ho (1983)
Richard Hornick (1983)
L. H. Huang (1982)
Milton Huppert (1983)
George Gee Jackson (1983)
William J. Jusko (1983)
Donald Kaye (1982)
Jerome O. Klein (1982)
George S. Kobayashi (1982)
Donald J. Krogstad (1983)
Felix Leitner (1983)
Stephen A. Lerner (1983)
Matthew E. Levison (1981)
Stuart B. Levy (1983)
Friedrich C. Luft (1981)
Joan Lusk (1983)
R. Luthy (1983)
Gerald Medoff (1983)
Barbara Minshew (1982)
Robert C. Moellering, Jr. (1982)
R. B. Morin (1982)
Bernard Moss (1981)
John D. Nelson (1983)
Harold C. Neu (1983)
J. F. Niblack (1983)
T. J. Perun (1983)
Charles A. Plate (1982)
Burton M. Pogell (1981)
K. E. Price (1982)
Paul Quie (1983)
Michael Rein (1983)
W. H. G. Richards (1983)
Mark H. Richmond (1982)
Richard Roberts (1982)
Ian M. Rollo (1982)
Richard Root (1983)
John P. Rosazza (1983)
Jon E. Rosenblatt (1982)
Milton R. J. Salton (1981)
Merle Sande (1982)
Arthur K. Saz (1982)
Jerome J. Schentag (1982)
F. C. Sciavolino (1982)
Oldrich K. Sebek (1983)
William M. Shannon (1983)
Charles Shipman, Jr. (1982)
Robert W. Sidwell (1981)
Walter Siegenthaler (1983)
P. Frederick Sparling (1981)
Brian G. Spratt (1983)
R. Sutherland (1982)
Vera L. Sutter (1981)
Morton N. Swartz (1982)
Richard B. Sykes (1982)
Alexander Tomasz (1982)
Ralph Tompsett (1982)
Hamao Umezawa (1981)
Donald Van Harken (1982)
Michael Waring (1981)
John Washington II (1981)
Pamela Waterworth (1982)
Jerry A. Weisbach (1982)
Bernard Weisblum (1982)
Peter G. Welling (1982)
Richard Wenzel (1983)

Walter G. Peter III, *Managing Editor*
Gisella Pollock, *Assistant Managing Editor*
Eleanor Tupper, *Production Editor*
1913 I St., NW, Washington, DC 20006

EX OFFICIO

Albert Balows, *President* (1980–1981)
J. Mehsen Joseph, *Secretary*

Frederick C. Neidhardt, *President-Elect* (1980–1981)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents, anticancer agents, and chemotherapy. Instructions to Authors are published in the January issue each year; reprints are available from the Editors and the Publications Office. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is $90 per year. The member subscription price is $25 per year. Single copies are $9. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

日本：価格は外貨表示とは関係なく円建。

Second class postage paid at Washington, DC 20006, and at additional mailing offices.
Made in the United States of America.
Copyright © 1981, American Society for Microbiology.
All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

Volume 19 Contents for January 1981 Number 1

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Role of the 7α-Methoxy and Side-Chain Carboxyl of Moxalactam in β-Lactamase Stability and Antibacterial Activity. KAZUHISA MURAKAMI* AND TADASHI YOSHIDA 1–7

Inhibition of Hepatitis B Virus Deoxyribonucleic Acid Polymerase by the 5′-Triphosphates of 9-β-D-Arabinofuranosyladenine and 1-β-D-Arabinofuranosylcytosine. GEORG HESS, WOLFGANG ARNOLD, AND KARL-HERMANN MEYER ZUM BÜSCHENFELDE* 44–50

R Plasmid with Carbadox Resistance from *Escherichia coli* of Porcine Origin. KENICHI OHMAE,* SHOICHI YONEZAWA, AND NOBUYUKI TERAKADO 86–90

Genetic Study of Plasmid-Associated Zonal Resistance to Lincomycin in *Streptococcus pyogenes*. HORST MALKE,* WERNER REICHARDT, MANFRED HARTMANN, AND FRIEDRICH WALTER 91–100

Liquid Chromatographic Assay of Ketoconazole. FRED A. ANDREWS,* LANCE R. PETERSON, WILLIAM H. BEGGS, DAUNE CRANKSHAW, AND GEORGE A. SAROSI 110–113

Grahamimycins: Antibiotics from *Cytospora* sp. Ehrenb. W.F.P.L. 13A. S. GURUSIDDAIAH AND R. C. RONALD* 153–165

Mutational Loss of Susceptibility to Mutacin GS-5 in *Streptococcus pyogenes*: Surface Protein in a Tolerant Variant. COLIN K. FRANKER 166–169

Increase in Colony-Forming Units of *Candida albicans* After Treatment with Polyene Antibiotics. JANINA BRAJTBURG, SVETLANA ELBERG, GERALD MEDOFF, AND GEORGE S. KOBAYASHI*. 199–200

Physiological Effects and Microbial Susceptibility

In Vitro Susceptibility of *Salmonella* to Various Antimicrobial Agents, Including a New Cephalosporin, Ro 13-9904. P. Y. CHAU,* W. S. NG, J. LING, AND K. ARNOLD 8–11

Neisseria gonorrhoeae Strains Isolated in Hong Kong: In Vitro Susceptibility to 13 Antibiotics. W. S. NG, P. ANTON, AND K. ARNOLD* 12–17

Antibacterial and Antifungal Activities of Benzimidazole and Benzoxazole Derivatives. ELAMIN I. ELNIMA,* M. UPPAL ZUBAIR, AND ABDULLAH A. AL-BADR 29–32

Effects of Penicillin on Group A Streptococci: Loss of Viability Appears to Precede Stimulation of Release of Lipoteichoic Acid. ROBERT E. KESSLER AND IVO VAN DE RIJN* 39–43

Susceptibility of Anaerobic Bacteria to Nine Antimicrobial Agents and Demonstration of Decreased Susceptibility of *Clostridium perfringens* to Penicillin. THOMAS J. MARRIE,* E. VANORA HALDANE, CAROL A. SWANTEE, AND ELIZABETH A. KERR 51–55

Activity of a New Cephalosporin Antibiotic, Ro 13-9904, Against Dense Populations of Selected Enterobacteria. DAVID GREENWOOD* AND ADRIAN ELEY 66–71

Limited In Vitro Activity of Cefamandole Against 100 Beta-Lactamase- and Non-Beta-Lactamase-Producing *Haemophilus influenzae* Strains: Comparison of Moxalactam, Chloramphenicol, and Ampicillin. MICHEL G. BERGERON,* SUZANNE CLAVEAU, AND PIERRE SIMARD 101–105

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

Comparative In Vitro Susceptibility of Yeasts to Amphotericin B and Three Methyl Ester Derivatives. DONNA L. OBLACK, WILLIAM L. HEWITT, AND WILLIAM J. MARTIN* 106–109

In Vitro Activity of *N*-Formimidoyl Thienamycin (MK0787) Against Resistant Strains of *Pseudomonas aeruginosa*, *Staphylococcus epidermidis*, *Serratia marcescens*, and *Enterococcus* spp. W. K. LIVINGSTON,* A. M. ELLIOTT, AND C. G. COBBS 114–116

Antibacterial Activity of Fortimicin A Compared with Those of Five Other Aminoglycosides, and Factors Affecting Susceptibility Tests. CLYDE THORNSBERRY,* A. L. BARRY, R. N. JONES, C. N. BAKER, R. E. BADAL, AND R. R. PACKER 122–129

Correlation of Moxalactam (LY127935) Susceptibility Tests by Disk Diffusion and Agar Plate Dilution Methods. WENDELL H. HALL* AND BONNIE J. OPFER 130–133

Antimicrobial Susceptibility of *Capnocytophaga*. SUSAN W. FORLENZA,* MICHAEL G. NEWMAN, ANN L. HORIKOSHI, AND UZY BLACHMAN 144–146

Comparison of the Effects of Arabinosyladenine, Arabinosylhypoxanthine, and Arabinosyladenine 5′-Monophosphate Against Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus with Their Effects on Cellular Deoxyribonucleic Acid Synthesis. JEFFREY F. GEPHART AND A. MARTIN LERNER* 170–178

Purification and Some Properties of a Cephalosporinase from *Proteus vulgaris*. NOBUYUKI MATSUBARA,* AKIRA YOTSUJI, KATSUHIKO KUMANO, MATSUHISA INOUE, AND SUSUMU MITSUHASHI 185–187

In Vitro Comparison of Dibekacin and Gentamicin Activities. CARTER D. HILL, GEORGE W. COUNTS, AND MARVIN TURCK* 190–192

Combined In Vitro Effect of Amphotericin B and Rifampin on *Cryptococcus neoformans*. NORMAN K. FUJITA* AND JOHN E. EDWARDS, JR. 196–198

N-Formimidoyl Thienamycin (MK0787): In Vitro Study. SMITH SHADOMY* AND RICHARD S. MAY 201–204

In Vitro Susceptibility of *Mycobacterium fortuitum to Cefoxitin*. MICHAEL H. CYNAMON* AND ALAN PATAPOW 205–207

Pharmacology and Therapeutics

Evaluation of Cefoxitin Nephrotoxicity in Experimentally Induced Renal Failure. DOUGLAS J. ORMROD AND THOMAS E. MILLER* 18–21

Suction Skin Blister, Skin Window, and Skin Chamber Techniques to Determine Extravascular Passage of Cefotaxime in Humans. R. F. FRONGILLO,* L. GALUPPO, AND A. MORETTI 22–28

Resistance Among Fecal Flora of Patients Taking Sulfamethoxazole-Trimethoprim or Trimethoprim Alone. RICHARD L. GUERRANT,* SHEILA J. WOOD, LINDA KRONGAARD, ROBERT A. REID, AND ROBERT H. HODGE 33–38

Cefmenoxime (SCE-1365), a Novel Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities. KANJI TSUCHIYA,* MASAHIRO KONDO, MAKOTO KIDA, MASAFUMI NAKAO, TOMOYUKI IWAHI, TAKESHI NISHI, YUMIKO NOJI, MARIKO TAKEUCHI, AND YUKIMASA NOZAKI 56–65

Anti-*Pseudomonas* Activity in Bronchial Secretions of Patients Receiving Amikacin or Tobramcyin as a Continuous Infusion. G. MOMBELLI, L. COPPENS, J. P THYS, AND J. KLASTERSKY* 72–75

Efficacy of Ampicillin Therapy in Experimental Listeriosis in Mice with Impaired T-Cell-Mediated Immune Response. IRMA A. J. M. BAKKER-WOUDENBERG,* P. DE BOS, W. B. VAN LEEUWEN, AND M. F. MICHEL 76–81

Sulfonamide and Trimethoprim Concentrations in Human Serum and Skin Blister Fluid. JOHAN N. BRUUN,* NILS ØSTBY, JAN E. BREDESEN, PETER KIERULF, AND PER KNUT M. LUNDE ... 82–85

Evaluation of Rosaramicin Phosphate in Treatment of Experimental Syphilis in Rabbits. ROBERT E. BAUGHN,* DANIEL M. MUSHER, CYNTHIA B. ADAMS, AND JOHN M. KNOX 117–121

Comparison of Antibacterial and Antiimmune Effects of Certain Rifamycins. J. E. KASIK* AND M. MONICK 134–138

Sensitive Radioimmunoassay for Vancomycin. KEI-LAI L. FONG, DAH-HSI W. HO,* LAURIE BOGERD, THERESA PAN, NITA S. BROWN, LAYNE GENTRY, AND GERALD P. BODEY, SR. 139–143

Amikacin and Gentamicin Accumulation Pharmacokinetics and Nephrotoxicity in Critically Ill Patients. MARGARET A. FRENCH, FRANK B. CERRA, MARTIN E. PLAUT, AND JEROME J. SCHENTAG* 147–152

Experimental Intraabdominal Candidiasis in Rabbits: Therapy with Low-Total-Dose Intravenous Amphotericin B. ARNOLD S. BAYER,* JOHN E. EDWARDS, JR., AND LUCIEN B. GUZE 179–184

Comparative Activities of AM-715 and Pipemidic and Nalidixic Acids Against Experimentally Induced Systemic and Urinary Tract Infections. KEIJI HIRAI,* AKIRA ITO, YASHUO ABE, SEIGO SUZUE, TSUTOMU IRIKURA, MATSUHISA INOUE, AND SUSUMU MITSUHASHI 188–189

Short-Course Human Leukocyte Interferon in Treatment of Herpes Zoster in Patients with Cancer. THOMAS C. MERIGAN,* JAMES G. GALLAGHER, RICHARD B. POLLARD, AND ANN M. ARVIN ... 193–195

Errata

Binding of Cycloheximide to Ribosomes from Wild-Type and Mutant Strains of *Saccharomyces cerevisiae*. WALTER STÖCKLEIN AND WOLFGANG PIEPERSBERG 208

Bactericidal Activity of Cerumen. TUU-JYI CHAI AND TOBY C. CHAI 208

Susceptibility of *Eikenella corrodens* to Newer Beta-Lactam Antibiotics. ELLIE J. C. GOLDSTEIN, MYLES E. GOMBERT, AND EMMANUEL O. AGYARE 208

Tentative Interpretive Criteria for the Diffusion Susceptibility Test Using 30-μg Netilmicin Disks. RONALD N. JONES, ARTHUR L. BARRY, AND CLYDE THORNSBERRY 208

Volume 19 Contents for February 1981 **Number 2**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Metabolic Regulation in Tylosin-Producing *Streptomyces fradiae*: Phosphate Control of Tylosin Biosynthesis. K. VU-TRONG, S. BHUWAPATHANAPUN, AND P. P. GRAY* 209–212

Preferential Inhibition of Ribonucleic Acid Synthesis by a New Thiosemicarbazone Possessing Antibacterial and Antiparasitic Properties. R. E. BROWN, F. A. STANCATO, AND A. D. WOLFE* 234–237

Repair of Membrane Alterations Induced in Baby Hamster Kidney Cells by Polyene Macrolide Antibiotics. BARBARA MALEWICZ, HOWARD M. JENKIN,* AND EDWARD BOROWSKI 238–247

Ribosomal Binding Region for the Antibiotic Tiamulin: Stoichiometry, Subunit Location, and Affinity for Various Analogs. GREGOR HÖGENAUER* AND CHRISTINE RUF 260–265

Properties of Penicillin-Binding Proteins in *Neisseria gonorrhoeae*. ALAN G. BARBOUR 316–322

Primaquine: Metabolism by Microorganisms and ^{13}C Nuclear Magnetic Resonance Assignments. ALICE M. CLARK, CHARLES D. HUFFORD, AND JAMES D. MCCHESNEY* 337–341

Effects of Ethambutol on Phospholipid Metabolism in *Mycobacterium smegmatis*. JAMES O. KILBURN,* KUNI TAKAYAMA, EMMA LEE ARMSTRONG, AND JOSEPH GREENBERG 346–348

Mode of Action of *Myxococcus xanthus* Antibiotic TA. DINA ZAFRIRI, EUGENE ROSENBERG,* AND DAVID MIRELMAN 349–351

Physiological Effects and Microbial Susceptibility

Inhibition of Vaccinia Virus Maturation by Zinc Chloride. EHUD KATZ* AND EVA MARGALITH 213–217

In Vitro Activity of Ro 13-9904, a New β-Lactamase-Stable Cephalosporin. LUDO VERBIST* AND JAN VERHAEGEN 222–225

In Vitro Activity of *N*-Formimidoyl Thienamycin, Moxalactam, and Other New Beta-Lactam Agents Against *Bacteroides fragilis*: Contribution of Beta-Lactamase to Resistance. JAMES E. BROWN, VICTOR E. DEL BENE,* AND CYNTHIA D. COLLINS 248–252

Antibiotic Resistance and R-Factors in the Fecal Coliform Flora of Urban and Rural Dogs. CATRIONA MONAGHAN, UNA TIERNEY, AND EMER COLLERAN* 266–270

Susceptibility of Shigellae to Mecillinam, Nalidixic Acid, Trimethoprim, and Five Other Antimicrobial Agents. HANS B. HANSSON,* MATS WALDER, AND INGMAR JUHLIN 271–273

Macrolide-Lincosamide-Streptogramin Resistance Patterns in *Clostridium perfringens* from Animals. GUNINDRA N. DUTTA AND LUC A. DEVRIESE* 274–278

Stimulation of Human and Canine Neutrophil Metabolism by Amphotericin B. SEE-RUERN SUPAPIDHAYAKUL, LILIA R. KIZLAITIS, AND BURTON R. ANDERSEN* 284–289

In Vitro Antibacterial Activity of Fluorinated Analogs of Chloramphenicol and Thiamphenicol. VASSILIKI P. SYRIOPOULOU, ALICE L. HARDING, DONALD A. GOLDMANN, AND ARNOLD L. SMITH* 294–297

Comparative Synergistic Activity of Cefoperazone, Cefotaxime, Moxalactam, and Carbenicillin, Combined with Tobramycin, Against *Pseudomonas aeruginosa*. LAWRENCE MINTZ* AND W. LAWRENCE DREW 332–334

Effect of Carbon Dioxide and pH on Susceptibility of *Bacteroides fragilis* Group to Erythromycin. SHARON L. HANSEN,* PATRICIA SWOMLEY, AND GEORGE DRUSANO 335–336

Isolation of Antibiotic-Resistant *Salmonella krefeld* from Clinical Veterinary Materials. JOHN J. MATHEWSON,* RUSSELL B. SIMPSON, AND DAVID A. ROUSH 355–356

In Vitro Susceptibilities of *Aeromonas hydrophila* to 32 Antimicrobial Agents. ROBERT J. FASS* AND JEAN BARNISHAN 357–358

Mezlocillin Susceptibility Tests by the Single-Disk Agar Diffusion Method. ROBERT J. FASS* AND RICHARD B. PRIOR 359–360

Inconsistency of Synergy Between the β-Lactamase Inhibitor CP-45,899 and β-Lactam Antibiotics Against Multiply Drug-Resistant *Enterobacteriaceae* and *Pseudomonas* Species. ROBERT J. FASS 361–363

Effect of Ribavirin on Rous Sarcoma Virus Transformation. FRANK J. JENKINS* AND YOUNG C. CHEN 364–368

Permeability and Susceptibility of *Escherichia coli* to β-Lactam Compounds. DAVID CLARK 369–370

Pharmacology and Therapeutics

Moxalactam (LY127935) in Treatment of Meningitis Due to Gram-Negative Bacilli. JOHN F. FISHER,* MARY JO CARTER, JANIS PARSONS, AND J. PETER RISSING 218–221

Comparative Toxicity of Amantadine Hydrochloride and Rimantadine Hydrochloride in Healthy Adults. FREDERICK G. HAYDEN,* JACK M. GWALTNEY, JR., ROBERT L. VAN DE CASTLE, KATHERINE F. ADAMS, AND BRUNO GIORDANI 226–233

Cefoxitin Disposition During Peritoneal Dialysis. WAYNE L. GREAVES, JOHN H. KREEFT, RICHARD I. OGILVIE,* AND GEOFFREY K. RICHARDS 253–255

Evaluation of Ceforanide as Treatment for Staphylococcal and Streptococcal Endocarditis. RONALD H. COOPER, CARY B. SAVITCH, W. PATRICK JOSEPH, AND JOHN MILLS* 256–259

Pharmacokinetics of Piperacillin in Patients with Moderate Renal Failure and in Patients Undergoing Hemodialysis. JOSE A. GIRON, BURT R. MEYERS, SHALOM Z. HIRSCHMAN,* AND ELINA SRULEVITCH 279–283

Effect of Antibiotics on the Prevalence of Enterotoxigenic *Escherichia coli* in Two Populations in the Philippines. PETER ECHEVERRIA,* PROCESO A. MEJIA, AND CHIRAPHUN DUANGMANI 290–293

Comparative Pharmacokinetics of Cefoperazone and Cefamandole. SUBRAMANIAM SRINIVASAN, ELLIOT L. FRANCKE, AND HAROLD C. NEU* 298–301

Pharmacokinetics of Moxalactam and Cefazolin Compared in Normal Volunteers. SUBRAMANIAM SRINIVASAN, KWUNG P. FU, AND HAROLD C. NEU* 302–305

Effects of Vancomycin on Renal Function in Rats. GEORGE R. ARONOFF,* REBECCA S. SLOAN, CHARLES B. DINWIDDIE, JR., MICHAEL D. GLANT, NAOMI S. FINEBERG, AND FRIEDRICH C. LUFT 306–308

Biliary Concentrations of Piperacillin in Patients Undergoing Cholecystectomy. JOSE A. GIRON, BURT R. MEYERS, AND SHALOM Z. HIRSCHMAN* 309–311

Peritoneal Fluid Concentrations of Gentamicin in Patients with Spontaneous Bacterial Peritonitis. G. DALE RICHEY* AND CHARLES J. SCHLEUPNER 312–315

Comparison of Enzymatic and Liquid Chromatographic Chloramphenicol Assays. ALLAN F. WEBER, KENT E. OPHEIM, JEFFREY R. KOUP, AND ARNOLD L. SMITH* 323–325

Analysis of the In Vitro Interaction Between Vancomycin and Cholestyramine. CHRISTINE Y. KING AND STEVEN L. BARRIERE* 326–327

Treatment of Experimental *Salmonella typhimurium* Infection with Mecillinam and Ampicillin. THOMAS BUTLER,* C. W. SHUSTER, AND PETER DIXON 328–331

Effects of Rifampin on Biliary Lipids in Humans. KLAUS VON BERGMANN, JOSHUA FIERER, HENRY Y. I. MOK, AND SCOTT M. GRUNDY* 342–345

Amikacin Sulfate Levels in Human Serum and Bile. RAMÓN H. BERMÚDEZ,* AGRIPINO LUGO, CARLOS H. RAMÍREZ-RONDA, JOSÉ A. AMADEO, AND JAVIER MORALES 352–354

Volume 19 **Contents for March 1981** **Number 3**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Molecular Nature of a Streptomycin and Sulfonamide Resistance Plasmid (pBP1) Prevalent in Clinical *Escherichia coli* Strains and Integration of an Ampicillin Resistance Transposon (Tn*A*). ULRICH VAN TREECK, FREIDRICH SCHMIDT, AND BERND WIEDEMANN* 371–380

Differences Between Ceftizoxime and Its Stereoisomer in Antibacterial Activity and Affinity for Penicillin-Binding Proteins. YASUTAKA SHIGI, HITOSHI KOJO, MAMIKO WAKASUGI, AND MINORU NISHIDA* 393–396

Antibacterial Activity of 2′,3′-Dideoxyadenosine In Vivo and In Vitro. GEORGE BESKID,* BARNET ESKIN, ROY CLEELAND, JOANN SIEBELIST, AUDREY J. CAPPETTA, ANITA D. HILL, AND ROBERT H. GEIGER 424–428

Microbial Transformations of *N*-Methylcolchiceinamide. PATRICK J. DAVIS 465–469

Nifurzide, a Nitrofuran Antiinfectious Agent: Interaction with *Escherichia coli* Cells. ANNE DELSARTE, MICHEL FAWAY, JEAN-MARIE FRÈRE,* JACQUES COYETTE, CLAIRE-MICHÈLE CALBERG-BACQ, AND ERNST HEINEN 477–486

Filament Formation of *Fusobacterium nucleatum* Cells Induced by Mecillinam. TAKATOSHI ONOE, TOSHIO UMEMOTO, HIROSUKE SAGAWA, AND HIDEKAZU SUGINAKA* 487–489

Isolation and Identification of Gamma-Aminobutyric Acid in *Streptomyces lincolnensis*. WILLARD J. HAAK* AND LESTER M. REINEKE 493

Physiological Effects and Microbial Susceptibility

In Vitro Activity of Naftifine, a New Antifungal Agent. APOSTOLOS GEORGOPOULOS,* GABOR PETRANYI, HUBERT MIETH, AND JÜRGEN DREWS 386–389

β-Lactam Resistance in *Serratia marcescens*: Comparison of Action of Benzylpenicillin, Apalcillin, Cefazolin, and Ceftizoxime. NAOKI TAKATA, HIDEKAZU SUGINAKA,* SHOZO KOTANI, MICHIO OGAWA, AND GORO KOSAKI 397–401

In Vitro Activity of *N*-Formimidoyl Thienamycin in Comparison with Cefotaxime, Moxalactam, and Ceftazidime. LUDO VERBIST* AND JAN VERHAEGEN 402–406

Comparison of In Vitro Activities of Eight β-Lactamase-Stable Cephalosporins Against β-Lactamase-Producing Gram-Negative Bacilli. LUDO VERBIST 407–413

Antibacterial Activity of Ceftriaxone (Ro 13-9904), a β-Lactamase-Stable Cephalosporin. HAROLD C. NEU,* NEAL J. MEROPOL, AND KWUNG P. FU 414–423

Development and Validation of a Neutralizer System for In Vitro Evaluation of Some Antiseptics. WAHEED SHEIKH 429–434

Comparative In Vitro Studies of Ro 13-9904, a New Cephalosporin Derivative. T. C. EICKHOFF* AND J. EHRET 435–442

In Vitro Comparison of Third-Generation Cephalosporins, Piperacillin, Dibekacin, and Other Aminoglycosides Against Aerobic Bacteria. LYNN PULLIAM,* W. KEITH HADLEY, AND JOHN MILLS 490–492

Pharmacology and Therapeutics

Prevention of Acute and Chronic Ascending Pyelonephritis in Rats by Aminoglycoside Antibiotics Accumulated and Persistent in Kidneys. JACQUES BILLE AND MICHEL P. GLAUSER* 381–385

In Vivo Antimycotic Activity of Naftifine. GABOR PETRANYI,* APOSTOLOS GEORGOPOULOS, AND HUBERT MIETH 390–392

Pharmacokinetics of Cefuroxime in Normal and Impaired Renal Function: Comparison of High-Pressure Liquid Chromatography and Microbiological Assays. ROBERT W. BUNDTZEN, ROGER D. TOOTHAKER, OLE S. NIELSEN, PAUL O. MADSEN, PETER G. WELLING, AND WILLIAM A. CRAIG* 443–449

Piperacillin Pharmacokinetics in Subjects with Chronic Renal Failure. MARIETTA I. B. THOMPSON, MARY E. RUSSO,* JOHN M. MATSEN, AND ELISABET ATKIN-THOR 450–453

Antimicrobial Activity of Cefmenoxime (SCE-1365). JOHN M. STAMM,* ROLAND L. GIROLAMI, NATHAN L. SHIPKOWITZ, AND ROBERT R. BOWER 454–460

Pharmacokinetics of Moxalactam in Patients with Renal Insufficiency. MILDRED LAM, CARL V. MANION, AND ANTHONY W. CZERWINSKI* 461–464

Antiviral Activity of Win 41258-3, a Pyrazole Compound, Against Herpes Simplex Virus in Mouse Genital Infection and in Guinea Pig Skin Infection. F. PANCIC,* B. A. STEINBERG, G. D. DIANA, P. M. CARABATEAS, W. G. GORMAN, AND P. E. CAME 470–476

Volume 19

Contents for April 1981

Number 4

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Mecillinam Susceptibility of *Escherichia coli* K-12 Mutants Deficient in the Adenosine 3′,5′-Monophosphate System. NIGEL W. SCOTT AND COLIN R. HARWOOD* 540–544

Resistance to Antibiotic Synergism in *Streptococcus faecalis*: Further Studies with Amikacin and with a New Amikacin Derivative, 4′-Deoxy, 6′-*N*-Methylamikacin. STEPHEN B. CALDERWOOD, CHRISTINE WENNERSTEN, AND ROBERT C. MOELLERING, JR.* 549–555

Inhibition of *Escherichia coli* by Thioglycerol. KARREN K. JNSEN AND GEORGE T. JAVOR* 556–561

Outer Membrane Permeability Barrier Disruption by Polymyxin in Polymyxin-Susceptible and -Resistant *Salmonella typhimurium*. MARTTI VAARA* AND TIMO VAARA 578–583

Penicillin-Binding Proteins in *Haemophilus influenzae*. S. DANIEL MAKOVER,* ROSEMARY WRIGHT, AND ELIZABETH TELEP 584–588

Sequestration of the Chloroquine Receptor in Cell-Free Preparations of Erythrocytes Infected with *Plasmodium berghei*. COY D. FITCH* AND REKHA CHEVLI 589–592

In Vitro Induction of Resistance to Erythromycin by Its Metabolite. JAROSLAV MAJER 628–633

Inhibition of Respiratory Syncytial Virus-Host Cell Interactions by Mono- and Diamidines. E. J. DUBOVI,* J. D. GERATZ, S. R. SHAVER, AND R. R. TIDWELL 649–656

Nogalamycin Inhibits Ribonucleic Acid Synthesis in Growing and Developing Cells of the Slime Mold *Dictyostelium discoideum*. HERBERT L. ENNIS 657–665

Interaction of Haemocin with *Escherichia coli*. R. G. STREKER, R. A. VENEZIA, AND R. G. ROBERTSON* 668–671

Physiological Effects and Microbial Susceptibility

Myxothiazol, a New Antibiotic Interfering with Respiration. GEORG THIERBACH* AND HANS REICHENBACH 504–507

Comparison of the Activity of Ionophores with Other Antibacterial Agents Against Anaerobes. KIMIHIRO WATANABE, JUNKO WATANABE, SAYOKO KURAMITSU, AND HIROMI B. MARUYAMA* 519–525

Rapid Radiometric Method for Determining Drug Susceptibility of *Mycobacterium avium-intracellulare*. BIENVENIDO G. YANGCO,* EDWARD A. EIKMAN, DAVID A. SOLOMON, STANLEY C. DERESINSKI, AND JOSEPH A. MADDEN 534–539

Isolating Specific Auxotrophic Mutants of *Mycobacterium smegmatis* by Using Vancomycin. CHARLES L. WOODLEY,* JACK N. BALDWIN, AND JOSEPH GREENBERG 571–574

Antimicrobial Susceptibility of *Campylobacter jejuni* with Special Reference to Resistance Patterns of Canadian Isolates. M. A. KARMALI, S. DE GRANDIS, AND P. C. FLEMING* 593–597

In Vitro and In Vivo Antibacterial Effects of Combinations of Beta-Lactam Antibiotics. NYDIA A. KUCK,* RAYMOND T. TESTA, AND MARTIN FORBES 634–638

Screening of *Neisseria gonorrhoeae* for Tolerant Response to Beta-Lactam Antiobiotics. LOUIS DE REPENTIGNY AND PIERRE L. TURGEON* 645–648

In Vitro Susceptibility of *Gardnerella vaginalis* to High Concentrations of Sulfonamide Compounds. BRIAN M. JONES* AND MUKTI N. BHATTACHARYYA 666–667

Combined Antiviral Effect of Interferon and Acyclovir on Herpes Simplex Virus Types 1 and 2. TREVOR L. STANWICK,* RAYMOND F. SCHINAZI, DONALD E. CAMBELL, AND ANDRE J. NAHMIAS 672–674

Susceptibility of Multiply Antibiotic-Resistant Pneumococci to the New Beta-Lactam Drugs and Rosaramicin. SHELDON H. LANDESMAN,* MARINELLA CUMMINGS, ANDREA GRUARIN, AND HARRIET BERNHEIMER 675–677

Effects of Halo Analogs of Glycerol 3-Phosphate and Dihydroxyacetone Phosphate upon *Escherichia coli*. BARRY MILDENER, THOMAS P. FONDY, ROBERT ENGEL, AND BURTON E. TROPP* 678–681

Antiviral Activity of 2-Acetylpyridine Thiosemicarbazones Against Herpes Simplex Virus. CHARLES SHIPMAN, JR.,* SANDRA H. SMITH, JOHN C. DRACH, AND DANIEL L. KLAYMAN 682–685

Pharmacology and Therapeutics

In Vitro and In Vivo Effects of Dapsone on Neutrophil and Lymphocyte Functions in Normal Individuals and Patients with Lepromatous Leprosy. R. ANDERSON,* E. M. S. GATNER, C. E. VAN RENSBURG, G. GRABOW, F. M. G. H. IMKAMP, S. K. KOK, AND A. J. VAN RENSBURG 495–503

Comparison of Five Methods for the Assay of Serum Gentamicin. RODNEY M. RATCLIFF,* CARLO MIRELLI, ELIZABETH MORAN, DENNIS O'LEARY, AND ROBYN WHITE 508–512

Trimethoprim-Rifampin, a New Combination Agent: Efficacy in Localized Urinary Infection and Influence on Microflora. ANNE-MARIE BOURGAULT, KEVIN R. FORWARD,* ALLAN R. RONALD, GODFREY K. HARDING, MARGARET THOMSON, AND GLORIA GREY 513–518

Pharmacology of Cefotaxime and Its Desacetyl Metabolite in Renal and Hepatic Disease. R. WISE, N. WRIGHT,* AND P. J. WILLS 526–531

Effects of Sodium Piperacillin on Platelet Function in Normal Volunteers. LAYNE O. GENTRY,* JOSEPH G. JEMSEK, AND ETHAN A. NATELSON 532–533

Penetrance of Nafcillin into Human Ventricular Fluid: Correlation with Ventricular Pleocytosis and Glucose Levels. RAM YOGEV,* WILLIAM E. SCHULTZ, AND SANFORD B. ROSENMAN 545–548

Cephamycin C Treatment of Induced Swine Salmonellosis. THOMAS M. JACKS,* C. JOSEPH WELTER, GERALD R. FITZERALD, AND BRINTON M. MILLER 562–566

Assays of Serum Aminoglycoside Levels by BACTEC 460 in the Presence of Cefamandole and Cefoxitin. L. E. PHILLIPS, R. F. MARTIN,* W. E. LUPER, AND T. E. ROGERS 567–570

Moxalactam Pharmacokinetics During Hemodialysis. GEORGE R. ARONOFF,* REBECCA S. SLOAN, STEVEN A. MONG, FRIEDRICH C. LUFT, AND STUART A. KLEIT 575–577

Comparative Efficacy and Safety of Nalidixic Acid Versus Trimethoprim/Sulfamethoxazole in Treatment of Acute Urinary Tract Infections in College-Age Women. ABDOLLAH IRAVANI,* GEORGE A. RICHARD, HERMAN BAER, AND ROBERT FENNELL 598–604

Pharmacokinetics of Gentamicin in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. SALVADOR PANCORBO* AND CHRISTINA COMTY 605–607

Single-Dose Pharmacokinetics of Acyclovir. STEPHEN A. SPECTOR,* JAMES D. CONNOR, MARIE HINTZ, RICHARD P. QUINN, M. ROBERT BLUM, AND RONALD E. KEENEY 608–612

Moxalactam and Cefazolin: Comparative Pharmacokinetics in Normal Subjects. W. MICHAEL SCHELD,* DANIEL A. SPYKER, GERALD R. DONOWITZ, W. KLINE BOLTON, AND MERLE A. SANDE 613–619

Latex Agglutination Inhibition Card Test for Gentamicin Assay: Clinical Evaluation and Comparison with Radioimmunoassay and Bioassay. HAROLD C. STANDIFORD,* DAVID BERNSTEIN, HENRY C. NIPPER, ELLIS CAPLAN, BEVERLY TATEM, JANET S. HALL, AND JACK REYNOLDS 620–624

Comparative Tissue Distribution of Ceforanide, Cefazolin, and Cefamandole in Rats. FRANCIS H. LEE,* ROBERT D. SMYTH, AND DONALD R. VAN HARKEN 625–627

Clinical Pharmacology of Moxalactam in Patients with Malignant Disease. ELIHU H. ESTEY, SUSANNE S. WEAVER, DAH-HSI W. HO, AND GERALD P. BODEY* 639–644

Volume 19 Contents for May 1981 Number 5

Biosynthesis; Chemistry; Mechanisms of Actions and Resistance

Insensitivity of Peptidoglycan Biosynthetic Reactions to β-Lactam Antibiotics in a Clinical Isolate of *Pseudomonas aeruginosa*. DAVID MIRELMAN,* YAEL NUCHAMOWITZ, AND ETHAN RUBINSTEIN 687–695

Isoelectric Focusing of *Bacteroides melaninogenicus* Group β-Lactamases. ROGER M. TIMEWELL, IAN PHILLIPS,* JAN SÖDERHOLM, AND CARL-ERIK NORD 700–704

β-Lactam-Resistant *Pseudomonas aeruginosa* with Modified Penicillin-Binding Proteins Emerging During Cystic Fibrosis Treatment. ALLAN J. GODFREY,* LAWRENCE E. BRYAN, AND HARVEY R. RABIN 705–711

Comparative Inhibition of Influenza and Parainfluenza Virus Replication by Ribavirin in MDCK Cells. MICHAEL J. BROWNE 712–715

Altered Penicillin-Binding Proteins in Methicillin-Resistant Strains of *Staphylococcus aureus*. BARRY HARTMAN AND ALEXANDER TOMASZ* 726–735

Aminocyclitol-Modifying Enzymes Specified by Chromosomal Genes in *Staphylococcus aureus*. FRITZ H. KAYSER,* FRANÇOISE HOMBERGER, AND MARLYSE DEVAUD 766–772

Involvement of the Outer Membrane in Gentamicin and Streptomycin Uptake and Killing in *Pseudomonas aeruginosa*. ROBERT E. W. HANCOCK,* VALERIE J. RAFFLE, AND THALIA I. NICAS 777–785

Enhanced Transmembrane Proton Conductance in *Streptococcus mutans* GS-5 Due to Ionophores and Fluoride. ARTHUR D. EISENBERG AND ROBERT E. MARQUIS* 807–812

Transmissible Plasmids from *Campylobacter jejuni*. DIANE E. TAYLOR,* STEPHANIE A. DE GRANDIS, M. A. KARMALI, AND P. C. FLEMING 831–835

Inhibition of Mouse LM Cell Replication by Trifluorothymidine: Role of Cytosolic Deoxythymidine Kinase. BRIAN L. WIGDAHL* AND J. RODNEY PARKHURST 881–890

In Vitro and In Vivo Morphological Response of *Klebsiella pneumoniae* to Cefotiam and Cefazolin. MASAFUMI NAKAO, TAKESHI NISHI, AND KANJI TSUCHIYA* 901–910

Selective Inhibition of Herpesvirus Deoxyribonucleic Acid Synthesis by Acycloguanosine, 2′-Fluoro-5-Iodo-Aracytosine, and (*E*)-5-(2-Bromovinyl)-2′-Deoxyuridine. A. LARSSON* AND B. ÖBERG 927–929

Physiological Effects and Microbial Susceptibility

Synergism, Killing Kinetics, and Antimicrobial Susceptibility of Group A and B Streptococci. C. N. BAKER,* C. THORNSBERRY, AND R. R. FACKLAM 716–725

Hypersusceptibility of Penicillin-Treated Group B Streptococci to Bactericidal Activity of Human Polymorphonuclear Leukocytes. DIANE HORNE AND ALEXANDER TOMASZ* 745–753

Effect of Subinhibitory Concentrations of Mecillinam on the Serum Susceptibility of *Escherichia coli* Strains. PETER W. TAYLOR,* HOWARD GAUNT, AND FRANK M. UNGER 786–788

Susceptibility of Enterococci and *Listeria monocytogenes* to *N*-Formimidoyl Thienamycin Alone and in Combination with an Aminoglycoside. GEORGE M. ELIOPOULOS AND ROBERT C. MOELLERING, JR.* 789–793

Activity of Moxalactam and Cefotaxime Alone and in Combination with Ampicillin or Penicillin Against Group B Streptococci. SHELDON H. LANDESMAN,* MICHAEL L. CORRADO, CHARLES C. CHERUBIN, AND MARCELINO F. SIERRA 794–797

Physiological Properties of Penicillin-Binding Proteins in Group A Streptococci. LAURENT GUTMANN, RUSSELL WILLIAMSON, AND ALEXANDER TOMASZ* 872–880

Murein Synthesis and Beta-Lactam Antibiotic Susceptibility During Rod-to-Sphere Transition in a *pbpA*(Ts) Mutant of *Escherichia coli*. GIUSEPPE A. BOTTA* AND DIONIGIA BUFFA 891–900

Anomalous Cellular Morphology and Growth Characteristics of *Neisseria meningitidis* in Subminimal Inhibitory Concentrations of Penicillin G. L. G. NEIRINCK AND I. W. DEVOE* 911–916

Inactivation of Mycoplasmas by Long-Chain Alcohols. RONALD D. FLETCHER,* JOHN R. GILBERTSON, ANN C. ALBERS, AND JOHN D. WHITE 917–921

Combined Protective Effects of Interferon and Interferon Induction on Herpes Simplex and Ectromelia Virus Infections in Mice. JIRO IMANISHI,* MOTOO MATSUBARA, CHEN-JEU WON, HARUKO NOMURA, AND TSUNATARO KISHIDA 922–924

In Vitro Susceptibility of *Haemophilus influenzae* and *Neisseria gonorrhoeae* to Ro 13-9904 in Comparison with Other β-Lactam Antibiotics. W. S. NG, P.Y. CHAU, AND K. ARNOLD* 925–926

Evaluation of a New Latex Agglutination Inhibition Card Test for Determining Serum Gentamicin Levels. GARY V. DOERN,* RICHARD H. GLEW, DOUGLAS S. PARKER, ROSEMARY A. PAVUK, AND STEPHEN D. BROWN 930–933

Procedure for Assay of Tobramycin in Serum Containing Moxalactam. DAVID F. MAHONEY, T. F. BUTLER, AND J. R. TURNER* 934–936

Pharmacology and Therapeutics

Increase of the Intestinal Absorption of Gentamicin and Amikacin by a Nonionic Surfactant. ARDON RUBINSTEIN, ETHAN RUBINSTEIN,* ELKA TOITOU, AND MAX DONBROW 696–699

Pharmacokinetics of Erythromycin Ethylsuccinate and Estolate in Infants Under 4 Months of Age. PISESPONG PATAMASUCON, SMING KAOJARERN, HELEN KUSMIESZ, AND JOHN D. NELSON* 736–739

Moxalactam Therapy for a Wide Spectrum of Bacterial Infections in Adults. ROBERT W. TOFTE,* JOHN ROTSCHAFER, JOANNE SOLLIDAY, AND KENT B. CROSSLEY 740–744

Liquid Chromatographic Assay for Metronidazole and Tinidazole: Pharmacokinetic and Metabolic Studies in Human Subjects. INGRID NILSSON-EHLE,* BO URSING, AND PETER NILSSON-EHLE 754–760

Intrarenal Concentrations of Ampicillin in Acute Pyelonephritis. SYLVIE TROTTIER AND MICHEL G. BERGERON* ... 761–765

Cefoperazone Treatment of Experimental Endocarditis. RICHARD A. SNEPAR, JAIME CARRIZOSA, WILLIAM D. KOBASA, AND DONALD KAYE* ... 773–776

Treatment of Gonorrhea: Comparison of Cefotaxime and Penicillin. MARGARET L. SIMPSON, MOHAMMED Y. KHAN,* YOUSUF SIDDIQUI, ROBERT P. GRUNINGER, AND DAVID I. WIGREN ... 798–800

Therapy of Lower Respiratory Tract Infections with Moxalactam. JOSEPH R. LENTINO,* MICHAEL W. RYTEL, AND EVON MOORE ... 801–806

Bacteriological Aspects of Selective Decontamination of the Digestive Tract as a Method of Infection Prevention in Granulocytopenic Patients. HILLY G. DE VRIES-HOSPERS,* DIRK T. SLEIJFER, NANNO H. MULDER, DIRK VAN DER WAAIJ, HENDRIK O. NIEWEG, AND HENDRIK K. F. VAN SAENE ... 813–820

Pharmacokinetics of Cefoperazone in Normal Volunteers and Subjects with Renal Insufficiency. W. KLINE BOLTON,* W. MICHAEL SCHELD, DANIEL A. SPYKER, AND MERLE A. SANDE ... 821–825

Chemoprophylaxis with Cefoxitin and Cephalothin in Orthopedic Surgery: a Comparison. MITCHELL B. ROSENFELD, JAIME CAMPOS, KENNETH R. RATZAN,* AND ISABEL LAUREDO ... 826–830

Methicillin Distribution in Serum and Extravascular Fluid and Its Relevance to Normal and Damaged Heart Valves. FRANCIS M. GENGO* AND JEROME J. SCHENTAG ... 836–841

Treatment of Uncomplicated Urinary Tract Infections with Trimethoprim Versus Sulfisoxazole, with Special Reference to Antibody-Coated Bacteria and Fecal Flora. ABDOLLAH IRAVANI,* GEORGE A. RICHARD, AND HERMAN BAER ... 842–850

Pharmacokinetics of Cefamandole in Osseous Tissue. ROGER J. LUNKE, ROBERT H. FITZGERALD, JR.,* AND JOHN A. WASHINGTON II ... 851–858

Comparative Nephrotoxicity of Gentamicin and Tobramycin: Pharmacokinetic and Clinical Studies in 201 Patients. JEROME J. SCHENTAG,* MARTIN E. PLAUT, AND FRANK B. CERRA ... 859–866

Gingival Crevicular Fluid Levels of Clindamycin Compared with Its Minimal Inhibitory Concentrations for Periodontal Bacteria. CLAY B. WALKER,* JEFFREY M. GORDON, HOWARD A. CORNWALL, JOANNE C. MURPHY, AND SIGMUND S. SOCRANSKY 867–871

Effect of Acyclovir on Latent Herpes Simplex Virus Infections in Trigeminal Ganglia of Mice. RICHARD J. KLEIN,* EUGENE DESTEFANO, ALVIN E. FRIEDMAN-KIEN, AND EILEEN BRADY ... 937–939

Errata

Phlebitis Induced by Parenteral Treatment with Flucloxacillin and Cloxacillin: a Double-Blind Study. ÅKE SVEDHEM, KJELL ALESTIG, AND MARIANNE JERTBORN ... 940

Antibacterial Activity of Ceftriaxone (Ro 13-9904), a β-Lactamase-Stable Cephalosporin. HAROLD C. NEU, NEAL J. MEROPOL, AND KWUNG P. FU ... 940

Volume 19

Contents for June 1981

Number 6

Biosynthesis; Chemistry; Mechanisms of Actions and Resistance

Isolation of Cairomycins A and C. IBRAHIM R. SHIMI* AND SHADIA FATHEY 941–944

Aminoglycoside-Resistant Mutants of *Pseudomonas aeruginosa* Deficient in Cytochrome *d*, Nitrite Reductase, and Aerobic Transport. L. E. BRYAN* AND SALLENE KWAN 958–964

Transferable Tetracycline Resistance in *Clostridium difficile*. C. JEFF SMITH, SHELDON M. MARKOWITZ, AND FRANCIS L. MACRINA* 997–1003

Drug Resistance and R Plasmids of *Escherichia coli* Strains Isolated from Pigs, Slaughterers, and Breeders of Pigs in Japan. KIYOSHI SAIDA, YASUYOSHI IKE,* AND SUSUMU MITSUHASHI 1032–1036

Identification of R Plasmids Mediating Gentamicin Resistance from *Escherichia coli* Strains in Japan. YASUYOSHI IKE,* NORIKO FUJISAWA-KON, SHYOJI SHIMIZU, KAZUO MOTOHASHI, HAJIME HASHIMOTO, AND SUSUMU MITSUHASHI 1070–1072

Segregation of 5-Fluorocytosine-Resistant Variants by *Candida albicans*. WILLIAM L. WHELAN,* EVERETT S. BENEKE, ALVIN L. ROGERS, AND DAVID R. SOLL 1078–1081

Physiological Effects and Microbial Susceptibility

Enhanced Susceptibility of *Escherichia coli* to Intracellular Killing by Human Polymorphonuclear Leukocytes After In Vitro Incubation with Chloramphenicol. HENDRIK PRUUL,* BRUCE L. WETHERALL, AND PETER J. MCDONALD 945–951

Molecular and Phenotypic Characterization of Penicillinase-Producing *Neisseria gonorrhoeae* from Canadian Sources. JO-ANNE R. DILLON,* PETER DUCK, AND DAVID Y. THOMAS 952–957

Effects of Low Penicillin Concentrations on Cell Morphology and on Peptidoglycan and Protein Synthesis in a Tolerant *Streptococcus* Strain. MYRON MYCHAJLONKA 972–979

Effect of Ionized Calcium and Soluble Magnesium on the Predictability of the Performance of Mueller-Hinton Agar Susceptibility Testing of *Pseudomonas aeruginosa* with Gentamicin. EDMUNDO CASILLAS, MARGARET A. KENNY, BARBARA H. MINSHEW, AND FRITZ D. SCHOENKNECHT* 987–992

In Vitro and In Vivo Antibacterial Activity of FR-31564, a Phosphonic Acid Antimicrobial Agent. HAROLD C. NEU* AND TOSHIAKI KAMIMURA 1013–1023

Minimum Inhibitory and Bactericidal Concentrations of 44 Antimicrobial Agents Against Three Standard Control Strains in Broth with and Without Human Serum. LARRY G. REIMER,* CHARLES W. STRATTON, AND L. BARTH RELLER 1050–1055

Heterogeneity of Antibiotic Resistance in Mucoid Isolates of *Pseudomonas aeruginosa* Obtained from Cystic Fibrosis Patients: Role of Outer Membrane Proteins. R. T. IRVIN,* J. W. R. GOVAN, J. A. M. FYFE, AND J. W. COSTERTON 1056–1063

Activity of Ceftazidime (GR 20263) Against Nosocomially Important Pathogens. J. M. T. HAMILTON-MILLER AND W. BRUMFITT* 1067–1069

Importance of Bacterial Growth Phase in Determining Minimal Bactericidal Concentrations of Penicillin and Methicillin. KWANG SIK KIM AND BASCOM F. ANTHONY* 1075–1077

Synergism in the Inhibition of *Bacillus subtilis* by Combinations of Lipophilic Weak Acids and Fatty Alcohols. THOMAS R. CORNER 1082–1085

Interaction Between Vancomycin and Rifampin Against *Staphylococcus aureus*. CHATRCHAI WATANAKUNAKORN* AND JOANN C. GUERRIERO 1089–1091

Pharmacology and Therapeutics

Pharmacokinetics of Moxalactam in Subjects with Normal and Impaired Renal Function. A. LEROY,* G. HUMBERT, AND J. P. FILLASTRE 965–971

Evaluation of Eight Cephalosporins in Hamster Colitis Model. JACK R. EBRIGHT,* ROBERT FEKETY, JOSEPH SILVA, AND KENNETH H. WILSON 980–986

In Vitro and In Vivo Synergism Between Amoxicillin and Clavulanic Acid Against Ampicillin-Resistant *Haemophilus influenzae* Type b. RAM YOGEV,* CHERYL MELICK, AND WILLIAM J. KABAT 993–996

Human Pharmacokinetics and Disposition of Sarmoxicillin, a Lipophilic Amoxicillin Prodrug. ROBERT D. SMYTH,* MORRIS PFEFFER, DONALD R. VAN HARKEN, ALBERT COHEN, AND G. H. HOTTENDORF 1004–1012

Nonparallel Nephrotoxicity Dose-Response Curves of Aminoglycosides. G. H. HOTTENDORF,* D. BARNETT, L. L. GORDON, E. F. CHRISTENSEN, AND H. MADISSOO 1024–1028

Pharmacokinetics of Netilmicin in Children with and Without Cystic Fibrosis. HELGE MICHALSEN AND TOM BERGAN* 1029–1031

Pharmacokinetics of Cefoperazone in Patients with Neoplastic Disease. ANDREW W. MAKSYMIUK, BARBARA M. LEBLANC, NITA S. BROWN, DAH-HSI HO, AND GERALD P. BODEY* 1037–1041

Plasma Disappearance, Urine Excretion, and Tissue Distribution of Ribavirin in Rats and Rhesus Monkeys. ELAINE A. FERRARA, JOHN S. OISHI, ROBERT W. WANNEMACHER, JR.,* AND EDWARD L. STEPHEN 1042–1049

Serum Aminoglycoside Assay by Enzyme-Mediated Immunoassay (EMIT): Correlation with Radioimmunoassay, Fluoroimmunoassay, and Acetyltransferase and Microbiological Assays. L. O. WHITE,* L. M. SCAMMELL, AND D. S. REEVES 1064–1066

Gynecomastia with Ketoconazole. RICHARD DEFELICE, DAVID G. JOHNSON, AND JOHN N. GALGIANI* 1073–1074

Comparative Pharmacokinetics of Cyclacillin and Amoxicillin in Infants and Children. CHARLES M. GINSBURG,* GEORGE H. MCCRACKEN, JR., TERESA G. ZWEIGHAFT, AND JOAN C. CLAHSEN 1086–1088

AUTHOR INDEX

VOLUME 20

Afarian, Joanne, 351
Ahonkhai, Vincent I., 850
Albritton, William L., 144
Alexander, G. A., 59
Alford, Robert H., 702
Alling, David W., 477
Al-Rawi, Zuhir Hashim, 25
Ånséhn, Steffan, 155
Armstrong, G. C., 356
Arnett, Gussie, 769
Aronoff, George R., 418
Atherton, Frank R., 470
Avent, C. K., 88
Azemun, Parviz, 168

Bacheson, Margaret A., 691
Baker, Carol J., 281
Baldwin, Jack N., 359
Baltz, Richard H., 214, 370
Bannatyne, Robert M., 493
Barnes, William G., 115
Barnett, B. B., 533
Baron, Stephen S., 814
Barry, A. L., 525
Barry, Arthur L., 197, 747, 760
Barza, Michael, 595, 809
Basker, Michael J., 38
Bassily, Samir B., 630
Bates, Theodore R., 81
Bauer, Eva, 496
Bauer, Larry A., 583
Baum, Jules, 595
Beam, Thomas R., Jr., 81
Bean, Bonnie, 378
Beaulieu, Bernard B., Jr., 410
Bedford, K. A., 30
Bedows, Elliott, 298
Bender, William J., 275
Benson, Charles E., 691
Bentley, Peter H., 38
Bernard, C., 463
Beskid, G., 159
Beutin, Lothar, 336
Black, Robert E., 104
Blaser, Jürg, 567
Blouin, Robert A., 583
Blue, William T., 547
Bodey, Gerald P., 226
Bodey, Gerald P., Sr., 718
Bokkenheuser, Victor D., 850
Bonetti, Antonio, 567
Bongaerts, Ger P. A., 344
Brammer, Keith W., 327
Brater, D. Craig, 487
Brier, Michael E., 418
Brockman, R. Wallace, 769
Brooks, M. A., 634
Brown, R. M., 356
Bruckner, David A., 239
Brückner, Oswald, 741
Bryson, Y. J., 787
Burch, Keith, 530
Burns, William H., 275, 286

Carlsson, Jan, 726
Carlton, William W., 387
Carrizosa, Jaime, 405
Cernich, Mark S., 556
Chadha, Kailash C., 653
Chen, S., 634
Cheng, Y.-C., 420
Cherubin, Charles E., 553, 850
Cheung, Rose, 493
Chmel, Herman, 688
Chodos, Dale J., 190
Chou, Wen-Gang, 443
Chow, Anthony W., 683
Christenson, J. G., 159
Cisneros, Luis A., 104
Clark, James E., 515
Clark, Scott M., 533
Clayton, J. Peter, 38
Cleeland, R., 159
Clements, Mary L., 104
Cobbs, C. G., 88
Cole, Martin, 38
Coleman, Dennis L., 252
Comber, Keith R., 38
Coombe, Reginald G., 75
Coppoc, Gordon L., 387
Coppola, John E., 53
Cordes, L. G., 793
Corrado, Michael, 688
Corrado, Michael L., 553
Cullinane, Joanne C., 307
Cumbo, Thomas J., 714
Cynamon, Michael H., 841

Dajani, Adnan S., 21, 208
Damper, P. Dianne, 803
da Silva Lopes, Antonio Alberto, 800
David, Hugo L., 666
Davis, Dave, 15
Davis, J. E., 272
de Bolster, Martinus W. G., 455
Delorenzo, W., 159
Demain, Arnold L., 508
de Miranda, Paulo, 518
de Oliveira, Moema M. G., 800
DiCioccio, Richard A., 653
Dickinson, Gordon M., 481
DiSanto, Anthony R., 190
Dismukes, W. E., 88
Dixon, Jill, 826
Dixon, Ronald A., 38, 321
Doern, Gary V., 696
Dougherty, Thomas J., 109
Dowling, J. N., 793
Droller, David G., 481
Drulak, Murray W., 683
Drusano, George L., 104
Drutz, D. J., 59
Dunkel, Edmund C., 580
Dutschman, G., 420

Edmondson, Robert A., 38
Edwards, David J., 714
Ehrlich, Sandra L., 351
Einhorn, Nina, 231
Eley, Adrian, 332
Elion, Gertrude B., 518
Elliott, A. M., 88
El-Masry, Nabil A., 630
Eng, Robert H. K., 688
Engineer, Meher S., 718
EORTC Antimicrobial Therapy Project Group, 463
Epstein, Wolfgang, 803

Fagerberg, Diane J., 777
Fainstein, Victor, 226
Familletti, Philip C., 1, 5
Farid, Zoheir, 630
Fasching, Claudine E., 378
Fayolle, Francoise, 314
Feeley, J. C., 793
Feingold, David S., 71
Felsenfeld, Ambhan D., 291
Fields, Branch T., Jr., 660
Fietta, Anna, 258
Finegold, Sydney M., 600, 705, 852
Fox, J. J., 420
France, Gene L., 660
Frehel, Claude, 666
Friedman, Harvey M., 691
Fuchs, Peter C., 197, 747
Furman, Phillip A., 518

Gabay, Elizabeth L., 852
Gaya, H., 463
George, Anthony M., 75
George, Beverly A., 777
Gerding, Dale N., 378
Gerlach, E. Hugh, 197, 747
Gerone, Peter J., 291
Girouard, Yves C., 144
Goldman, Peter., 410
Goldstein, Ellie J. C., 146, 705

Gombert, Myles E., 553
Gorman, G. M., 793
Goto, Mitsuyoshi, 393
Granich, George G., 272
Graybill, J. R., 59
Green, Mary T., 580
Greenberg, Stephen B., 648
Greenman, Richard L., 481
Greenstein, Michael, 425
Greenwood, David, 332
Gruninger, Robert P., 265, 681
Guze, Lucien B., 491

Hackman, M. R., 634
Hall, Michael J., 470
Hancox, J., 356
Handsfield, H. Hunter, 625, 839
Hansbrough, John F., 515
Harder, Karen J., 549
Hardin, Thomas C., 252
Hargadon, Michael T., 620
Hashimoto, Kazunori, 382
Hassall, Cedric H., 470
Heisler, Owen R., 53
Hinkle, Anne M., 226
Hinsman, Edward J., 387
Hirai, Keiji, 262
Hirsh, Dwight C., 415
Hjertén, Stellan, 563
Ho, Dah-Hsi W., 718
Hoffman, Thomas A., 481
Hoffstedt, Björn, 783
Hofmann, Tim, 821
Holmes, King K., 625, 839
Holmes, Simon W., 470
Horne, Diane, 128
Howard, Colin R., 826
Hughes, Colin, 496
Husson, Mireille, 267
Hutson, Duane, 231

Inoue, Matsuhisa, 262
Istre, Greg R., 244
Ito, Tomiyoshi, 136

Jackson, Derrick, 38
Janicke, David M., 590
Jochemsen, Aart-Gerrit, 455
Jones, David T., 437
Jones, R. N., 525
Jones, Ronald N., 197, 747, 760
Jorgensen, J. H., 59
Jorgensen, James H., 66
Jovanovich, John F., 530
Judson, Franklyn N., 625
Jusko, William J., 590

Kafetzis, Dimitris A., 487
Kager, L., 736
Kalmanson, George M., 491
Kampf, Dieter, 741
Kanarios, John, 487
Kane, Anne, 595
Kaplan, S. A., 634
Kaptijn, G. Marja P., 344
Kass, Edward H., 351
Katsumata, Ryoichi, 262
Kawabe, Haruhide, 33
Kessler, Harold A., 826
Khan, Mohammed Y., 265, 681
Kida, Makoto, 171
Kikuchi, Y., 176
Kilburn, James O., 401
Kilpatrick, Michael E., 630
Kim, Kenneth S., 696
Kirksey, Donny F., 547
Klastersky, J., 463, 539
Klastersky, Jean, 267
Kline, Berry J., 576
Knight, Paul R., 298
Knight, Vernon, 477
Kobos, Denise M., 208
Koch, Ronald L., 410
Koller, Antje E., 109
Kolling, William M., 587
Komatsu, Yoshihide, 613
Komiya, M., 176
Konikoff, J., 634
Korchik, William P., 378
Korsukewitz, Inge, 741
Kowalski, Bernadette, 336
Krogstad, Donald J., 272
Kuninaka, Akira, 47
Kuno, Mitsuzo, 171
Kurtz, Terrance O., 239
Kwok, Y. Y., 146, 270, 723
Kwok, Yung-Yuan, 705

Ladenson, Jack H., 272
Lagast, H., 539
Lambert, Robert W., 470
Lanata, Claudio F., 104
Landis, Stephan J., 693
Laudat, Patrice, 260
Lavelle, Kevin J., 418
Lazar, Arye, 151
Leong, John, 558
Lesourd, Maurice, 666
Levi, Joe U., 231
Levine, Myron M., 104
Levison, Matthew E., 405, 642
Levy, Stuart B., 307
Lewis, Robert P., 705
Liljeqvist, L., 736
Lindsey, Norma J., 115
Livingston, W. K., 88
Livingstone, Alan, 231
Lloyd, William J., 470
Longoria, Rose M., 477
Lüthy, Ruedi, 567

Machida, H., 420
Machida, Haruhiko, 47
Maclean, Ian W., 144
Magni, Lennart, 837
Maiese, William M., 425
Malinin, Theodore I., 231
Maller, Rolf, 155
Malmborg, A. S., 736
Mandell, Gerald L., 709
Mangione, Antoinette, 590, 714
Mangura, Carolina, 688
Mansheim, Bernard J., 693
Marchi, Antonietta, 258
Markowitz, Sheldon M., 576
Marks, Melvin I., 244
Marmer, Daniel J., 660
Marseglia, Gianluigi, 258
Martin, Lori D., 415
Martin, R. Russell, 648
Martin, William J., 239
Martinelli, Reinaldo, 800
Martinez, Octavio V., 231
Maskell, J. P., 433
Mason, Edward O., Jr., 281
Matson, Ronald E., 81
Matsubara, Nobuyuki, 262
Matsuhashi, Michio, 549
Matsuo, Yoshiyasu, 542
Maurer, Molly J., 21
McCandliss, Russell, 5
McClatchy, J. Kenneth, 556
McCloskey, Richard V., 140
McGee, Zell A., 702
McKinley, Geoffrey A., 777
McLafferty, Martha A., 410
McMurry, Laura M., 307
Merrikin, David J., 38
Michael, Paul R., 702
Mikhail, Isis A., 630
Miller, Timothy T., 847
Minah, Glenn E., 620
Minai, Moshe, 151
Miner, David J., 252
Mitsuhashi, Susumu, 33, 171, 262
Mizrahi, Avshalom, 151
Moellering, Robert C., Jr., 204
Monson, Thomas P., 847
Moore, Brian A., 327
Moore, D. F., 787
Moore, Rebecca V., 477
Moorman, David R., 709
Morris, Brian L., 580
Mosenthal, Anne C., 850
Mossie, Kevin G., 437
Moyer, Nelson, 244
Murakami, Kazuhisa, 613
Murphy, Timothy F., 809
Murphy, Victory L., 839
Murray, Patrick R., 66, 272, 686
Mylotte, Joseph M., 81

Nahrwold, Michael L., 298
Nakagawa, Shizutoshi, 542
Nakajima, Shinji, 393
Nasu, M., 433
Nauta, Wijbe T., 455
Neu, Harold C., 366, 398, 545
Ngui-Yen, John H., 678, 821
Nikaido, Hiroshi, 549
Niles, Ann C., 272, 686

Nilsson, Lennart, 155
Nisbet, Louis J., 470
Nishikawa, Tohru, 613
Nolan, Charles M., 847
Nord, C. E., 736
Nyberg, Göran K., 726

O'Brien, Thomas F., 351
O'Dell, C. Allen, 769
Oh, Jang O., 503
Ohayon, Hélène, 666
Ohyama, Akio, 136
Oill, Phyllis A., 491
Okonogi, Kenji, 171
Olay, Tránsito, 10

Palmer, Gregory S., 841
Papadatos, Constantine J., 487
Park, James T., 809
Parks, L. W., 184
Parsonnet, M., 634
Pasculle, A. W., 793
Patel, I. H., 634
Pennington, James E., 351
Person, Audrey, 688
Pestka, Sidney, 1, 5
Peterson, Lance R., 378
Petrucci, Richard E., Jr., 307
Pinon, Georges, 260
Platt, Richard, 351
Pogell, Burton M., 443
Pohlod, Donald J., 530
Poirier, Agnès, 508
Polk, Ron E., 576
Poporad, George, 642
Portnoy, David, 235
Preller, Elena, 336
Prentis, John, 235
Prince, Alice S., 545
Privitera, Gaetano, 314
Pyeatt, Denise, 270

Quentin, Roland, 260
Quinones, Frank J., 648

Ramphal, Reuben, 693
Rand, Kenneth H., 693
Rashad, Abdel L., 696
Rastogi, Nalin, 666
Reimer, Larry G., 515
Reuveny, Shaul, 151
Rhoades, Keith R., 415
Richards, Geoffrey K., 235
Riley, Thomas V., 731
Rinehart, K. L., Jr., 653
Ringrose, Peter S., 470
Riviere, J. Edmond, 387
Robb, Frank T., 437
Roberts, Anthony P., 496
Roberts, Marilyn, 168
Robertson, Janet A., 53
Robins-Browne, Roy M., 104
Rocha, Heonir, 800
Rodríguez, Antonio, 10
Rodriguez, R. J., 184
Rolfe, Rial D., 600, 852
Romano, Joseph, 642
Ronald, Allan R., 144
Rosenthal, Raoul S., 98
Rowe, John J., 814
Ryff, J. C., 463
Ryter, Antoinette, 666

Saah, Alfred J., 104
Sacchi, Fulvio, 258
Sahai Srivastava, B. I., 653
Sakata, Shinji, 47
Sanders, Christine C., 247, 843
Sanders, W. Eugene, Jr., 247
Sands, Jeffrey A., 699
Saral, Rein, 275, 286
Saravolatz, Louis D., 530
Sato, Kenichi, 262
Savage, Russell E., 547
Schentag, Jerome J., 714
Schimpff, Stephen C., 620
Schultz, Robert W., 590
Schurig, Randolf, 741
Scott, David R., 696
Sebald, Madeleine, 314
Sekizaki, Tsutomu, 382
Seno, Eugene T., 214, 370
Sergeant, Kim A., 81
Shands, Joseph W., Jr., 693
Shannon, William M., 769
Shealy, Y. Fulmer, 769
Shepherd, Alexander M. M., 252
Shiba, Tetsuo, 834
Shulman, Michael, 553
Shulman, Michael A., 850
Siccardi, Antonio G., 258
Sicher, Steven E., 503
Siddiqui, Yousuf, 265, 681
Sidwell, Robert W., 533
Siegenthaler, Walter, 567
Sierra, Marcelino F., 553, 850
Simmen, Hanspeter, 567
Simpson, Margaret L., 681
Sinaniotis, Constantine A., 487
Sinha, Rabindra K., 98
Sjövall, Jan, 837
Slocombe, Brian, 38
Smee, Donald F., 533
Smit, Hendrik, 455
Smith, Arnold L., 168
Smith, John A., 821
Smith, John S., 678
Snepar, Richard, 642
Sniffen, J. M., 793
Soike, Kenneth F., 291
Sommers, Herbert M., 747
Spendlove, Rex S., 533
Speth, John L., 425
Srinivasan, Subramaniam, 366, 398
St. Clair, Marty H., 518
Steele, Russell W., 660
Stobbs, Darlene G., 547
Stouthamer, Adrian H., 455
Stuart, Robert K., 286
Stull, Terrence, 168
Sud, Inder Jit, 71
Sugimoto, Yoshikazu, 120
Sugiyama, Masatoshi, 393
Sutherland, Robert, 38
Sutter, Vera L., 146, 270, 705, 723

Tabaqchali, Soad, 25
Tachibana, A., 176
Takayama, Kuni, 401
Tanimura, Eiki, 136
Taylor, S. C., 787
Terakado, Nobuyuki, 382
Teshima, Tadashi, 834
Thirumoorthi, M. C., 21, 208
Thornsberry, C., 525
Thornsberry, Clyde, 197, 747, 760
Thrupp, Lauri D., 15
Timmerman, Henk, 455
Tomasz, Alexander, 109, 128
Totten, Pat A., 359
Toyoshima, Shigeshi, 120
Traub, Abraham, 151
Trent, Judith A., 140
Trown, P. W., 159
Tsang, Anna Y., 556
Tsiquaye, Kwesi, 826
Tutlane, Victoria A., 140
Tylewska, Stanislawa, 563

van der Goot, Henderikus, 455
Vargues, Robert, 260
Vicente, María V., 10
Vidal, Lucy, 359
Vincent, Catherine V., 21
Vinnars, Erik, 837
Vis, Ronald D., 455

Wade, James C., 620
Wadström, Torkel, 563
Walder, Mats, 783
Wallace, Richard J., Jr., 610, 648
Ward, Joel I., 204
Washington, John A., II, 63
Watanabe, K. A., 420
Weeks, Janis L., 281
Welch, David F., 244
Welch, William D., 15
Westbrook, Louise, 769
Westmacott, Donald, 470
Weyant, R. S., 793
Wigmore, Margaret, 821
Williams, J. D., 433
Williams, R. J., 433
Wills, P. J., 30
Wilson, Harold W., 760
Wilson, Samuel Z., 477
Wingard, John R., 275, 286
Winland, Roger D., 547
Winston, Drew J., 239

Wise, R., 30, 356
Wise, Richard, 567
Wiss, Karen, 610
Woods, David R., 437

Yabuuchi, Eiko, 136
Yamada, Takeshi, 854
Yamagata, Somay, 382
Yamamoto, Norimi, 136
Yamamoto, Tomoko, 382
Yamashina, Hajime, 393
Yamashita, Kinya, 33
Yang, Chien-Chin, 558
Yano, K., 176
Yogev, Ram, 587
Yoshino, Hiroshi, 47
Young, Viola M., 620
Yu, Pauline K. W., 63

Zeppa, Robert, 231
Zinner, S. H., 463, 539
Zinner, Stephen H., 267
Zuckerman, Arie J., 826

SUBJECT INDEX

VOLUME 20

Acyclovir
  experimental simian varicella infection of monkeys, 291
  herpes simplex virus type 1 in rabbit tear film after treatment, 580
  metabolism in infected cells, 518
  mouse cytomegalovirus, efficacy in vivo, 275
  neonatal herpesvirus infections in rabbits, 503
  virus inhibition assay of levels in human plasma and urine, 787
Adenosine monophosphate
  effects on reactivation of latent herpesvirus in mice, 547
S-Adenosyl-L-methionine:macrocin *O*-methyltransferase assay in *S. fradiae*, 370
Agar dilution susceptibility
  Bacteroides spp., 731
  disk diffusion, comparison with, 731
  sulfamethoxazole, 731
  trimethoprim, 731
Alafosfalin
  plus cephalexin, 470
Alimentary tract flora
  selective suppression as prophylaxis in granulocytopenia, 620
Amikacin
  compared in vitro with Win 42122-2, 247
  E. coli resistance mediated by aminoglycoside phosphotransferase, 344
  intraventricular levels after intravenous dose, 583
  levels in human gallbladder bile & wall, 515
  synergy with new β-lactams, 239
  with azlocillin and cefotaxime, 463
Aminoglycoside adenylyltransferase, new
  adenylylates amikacin, 75
  plasmid-mediated, 75
Aminoglycoside antibiotics
  bacterial resistance, 803
  effects on neutrophil chemotaxis, 258
  inactivation by sodium polyanethol sulfonate, 272
  inhibition by heparin, 155
  role of membrane potential, 803
  synergy with penicillin in enterococcal endocarditis, 405
Aminoglycoside phosphotransferase
  mediates amikacin resistance in *E. coli*, 344
Amoxicillin
  chronic salmonella bacteriuria, 630
  β-lactamase-producing *H. ducreyi*, 144
  synergy with clavulanic acid vs. *H. ducreyi*, 144
Amoxicillin/clavulanic acid
  S. clavuligerus, 800
  urinary tract infections, 800
Amphotericin B
  hepatitis B virus, 826
  neutrophil toxicity, 660
  zygomycetes susceptibility, 688
Ampicillin
  antagonism with chloramphenicol vs. group B streptococci, 281
  chronic salmonella bacteriuria, 630
  plus rifampin, streptomycin in rat pyelonephritis, 491
  produg availability
    bacampicillin, 837
    talampicillin, 837
Anaerobes
  carbon dioxide, 705
  erythromycin, susceptibility to, 705
Anaerobic activity
  ceftizoxime, cefoperazone, cefoxitin compared, 683
Anaerobic bacteria
  cefoxitin, no tolerance, 146
  new β-lactams, comparative activity, 600
Anaerobic plate assay
  drugs in serum, 678
Anderson Technical semiautomated susceptibility testing system
  evaluation, 777
Antagonism
  ampicillin-chloramphenicol vs. group B streptococci, 281
Antimicrobial solutions
  effect of filtration, 686
Antiviral nucleoside analogs
  activity on viral and human thymidine kinases, 420
1-β-D-Arabinofuranosyl-*E*-5-(2-halogenovinyl)uracils
  anticellular effects, 47
  antiherpesviral effects, 47
Arginine
  regulation of gramicidin S biosynthesis, 508
Autobac-1
  susceptibility test disagreements with MS-2, 000
15-Azasterol
  inhibition of *S. cerevisiae*, 184
Azlocillin
  with cefotaxime and amikacin, 463

Bacampicillin
  bioavailability, 837
Bacterial resistance
  aminoglycoside antibiotics, 803
  role of membrane potential, 803
Bacteriocins
  B. fragilis, 437
  RNA polymerase sensitivity to, 437
  S. faecium, 542
Bacteriuria, *Salmonella*
  amoxicillin, ampicillin, 630
Bacteroides fragilis
  cefoperazone activity, 723
  in vitro comparative activity of ceftizoximes, 332
Bacteroides fragilis group
  transferability of plasmid-mediated drug resistance, 314
Bacteroides spp.

sulfamethoxazole susceptibility
agar dilution, 731
disk diffusion, 731
trimethoprim susceptibility
agar dilution, 731
disk diffusion, 731
Bile
moxalactam excretion, 231
Blood culture
direct disk diffusion susceptibility test, evaluation, 696
Bluetongue virus
inhibition by antivirals, 533
Body fluids
cefuroxime, fluorimetric assay, 25
moxalactam, determination methods, 252
BRL 17421, new β-lactam
activity, 38
serum levels in humans, 38

Campylobacter fetus subsp. *jejuni*
in vitro susceptibility
N-formimidoyl thienamycin, 850
Capnocytophaga
in vitro susceptibility to 18 drugs, 270
Carbenicillin
resistant *E. coli* mutants lacking a porin, 549
Carbodine
human influenza type A viruses, 769
Carbon dioxide
anaerobe susceptibility to erythromycin, 705
Cefamandole
childhood infections, 21
pharmacokinetics and blister fluid concentrations, 356
pharmacology, 366
Cefazolin
pharmacokinetics after intravenous infusion, 576
pneumonia, clinical trial, 648
Cefmenoxime (SCE-1365)
antibacterial activity, 171
comparison with other antimicrobial agents, 747
disk diffusion testing, 747
in vitro activity, 747
β-lactamase stability, 171, 747
Cefodizime (HR221)
evaluation in vitro, 760
Cefoperazone
activity vs. β-lactamase-producing *H. influenzae*, 63
B. fragilis group, 723
C. fetus subsp. *jejuni*, 850
comparative in vitro activity vs. anaerobes, 683
in vitro comparison with *N*-formimidoyl thienamycin, 140
with CP-45,899, 63
Ceforanide
pneumonia, clinical trial, 648
probenecid effect on pharmacokinetics, 530
Cefotaxime
clinical pharmacology in pediatric patients, 487
in vitro comparison with *N*-formimidoyl thienamycin, 140
multipled-dose pharmacokinetics, 567
plus tobramycin, 539
with azlocillin and amikacin, 463
Cefotazime
pelvic inflammatory disease, 847
Cefoxitin
comparative in vitro activity vs. anaerobes, 683
no tolerance in anaerobes, 146
pharmacokinetics, 741
renal clearance studies of patients with renal insufficiency, 741
Cefsulodin
activity, 525
tentative interpretive standards for disk susceptibility test, 525
Ceftazidime
multiple-dose pharmacokinetics, 567
pharmacokinetics and blister fluid concentrations, 356
Ceftizoxime
B. fragilis, in vitro comparative activity, 322
comparative in vitro activity vs. anaerobes, 683
glucose-nonfermenting gram-negative rods in vitro, 136
pharmacology, 366
Ceftriaxone
pharmacokinetics in humans, 634
uncomplicated gonorrhea in men, dose-ranging study, 839
Ceftriaxone (Ro 13-9904)
in vitro activity, 159
Cefuroxime
in body fluids, fluorimetric assay, 25
Cephalexin
plus alafosfalin, 470
Cephalosporin
cefodizime (HR221), 760
Cephalosporins
comparative in vitro study, 226
N-formimidoyl thienamycin, 841
N. asteroides, 841
penetration into interstitial fluid in humans
mode of administration, 783
serum protein binding, 783
Cephalothin
resistant infections, moxalactam therapy, 351
Cerebrospinal fluid
ketoconazole bioassay, 59
piperacillin penetration, 481
Childhood infections
cefamandole, 21
Chloramphenicol
antagonism with ampicillin vs. group B streptococci, 281
H. influenzae susceptibility, 208
R plasmids in *S. naestved* and *E. coli*, 382
transposons, 382
Chloroamphenicol
H. influenzae resistance, rapid detection, 168
Cinodine
mechanism of action, 425
Clavulanic acid
β-lactamase-producing *H. ducreyi*, 144
synergy with amoxicillin vs. *H. ducreyi*, 144
Clindamycin

colonic microflora in patients undergoing colorectal surgery, 736
Clostridium perfringens
penicillin-binding proteins, 809
Clostridium septicum
susceptibility to 23 antimicrobial agents, 852
Clotrimazole
action mechanisms compared, 71
N^{α}-Cocoyl-L-arginine ethyl ester
hepatitis B surface antigen inactivation, 120
Colonic microflora
clindamycin prophylaxis, 736
Colorado tick fever orbivirus
inhibition by antivirals, 533
CP-45,899
activity with cefoperazone, 63
Cystic fibrosis
new β-lactams vs. *P. aeruginosa*, 545
Cytidine analog
carbodine, 769
Cytomegalovirus
trifluorothymidine activity, assays, 286

Di-β-lysyl-capreomycin IIA
drug-resistant mutants with altered ribosomes, 834
Disk diffusion susceptibility testing
mezlocillin, tentative standards, 197
Disk duffison
agar dilution, comparison with, 731
Bacteroides spp., 731
sulfamethoxazole, 731
trimethoprim, 731
Disk zone susceptibility testing
cefsulodin, tentative standards, 525
direct blood culture test, 696

Endocarditis, enterococcal
aminoglycoside-penicillin synergy, 405
Endocarditis, experimental
S. sanguis, therapy, 10
Enflurane
inhibition of measles virus replication, 298
Entamoeba histolytica
metronidazole metabolism, 410
Erythromycin
anaerobe susceptibility, 705
carbon dioxide, 705
susceptibility of group A beta-hemolytic streptococci, 244
U. urealyticum susceptibility testing, 53
Erythromycin base
food effects on absorption, 190
study design influence, 190
Erythromycin stearate
food effects on absorption, 190
study design influence, 190
Escherichia coli
amikacin resistance mediated by aminoglycoside phosphotransferase, 344
carbenicillin-resistant mutants lacking a porin, 549
experimental meningitis in rabbits, 81
moxalactam penetration into proteins, 613
tetracycline uptake by membrane vesicles, 307
trimethoprim-sulfamethoxazole for experimental meningitis, 81
urinary tract infection isolates, R plasmid spread, 496
Escherichia coli, enterotoxigenic
Lactobacillus prophylaxis for diarrhea, 104
Ethambutol
effects on mycolate synthesis in *M. smegmatis*, 401

Food
effects on erythromycin absorption, 190
N-Formimidoyl thienamycin
activity against gram-positive cocci, 553
N-formimidoyl thienamycin
cephalosporins, 841
N-Formimidoyl thienamycin
C. fetus subsp. *jejuni*, 850
gentamicin-resistant *P. aeruginosa*, 702
in vitro activity against *Bacteroides* spp., 433
in vitro comparison, with new β-lactams, 140
N-formimidoyl thienamycin
N. asteroides, 841
Fortimicin A
P. aeruginosa, 33
synergy with β-lactams, 33
Fosfomycin
pharmacokinetics, 393

Gallbladder, human
amikacin levels, 515
kanamycin levels, 515
Gentamicin
compared in vitro with Win 42122-2, 247
measurement in serum, comparison of three methods, 821
mouse arthritis with *M. pulmonis*, 321
pharmacokinetics in glomerulonephritis, 387
Glomerulonephritis
canine, gentamicin, 387
Gonococcal urethritis
piperacillin, penicillin activities compared, 693
Gonorrhea
ceftriaxone, 839
rosoxacin, 625
Gramicidin S
biosynthesis, arginine regulation, 508
Gram-negative rods
ceftizoxime, 136
glucose nonfermenting, ceftizoxime activity, 136
Gram-positive bacteria
H. influenzae, 843
penicillins, 843
Gram-positive cocci
susceptibility, 553
Granulocytopenia
selective suppression of rectal flora, 620
Group A beta-hemolytic *Streptococcus*
penicillin, erythromycin susceptibility, 244
Group B *Streptococcus*
ampicillin-chloramphenicol antagonism, 281
pH-dependent penicillin tolerance, 128
Group C *Streptococcus*
penicillin tolerance in human isolates, 235
synergy of penicillin plus gentamicin, 235

Guanosine
interference with ribavirin antiviral protection in mice, 477

Haemophilus ducreyi
clavulanic acid plus amoxicillin, 144
susceptibility of β-lactamase producers, 144
Haemophilus influenzae
cefoperazone plus CP-45,899 vs. β-lactamase producers, 63
chloramphenicol resistance, rapid detection, 168
chloramphenicol susceptibility, 208
gram-positive bacteria, 843
β-lactams susceptibility, 208
penicillins, 843
Hemodialysis
moxalactam pharmacokinetics, 398
Hemodialysis, chronic
mezlocillin disposition, 590
Hemolysin
S. faecium, 542
Heparin
aminoglycoside inhibition, 155
Hepatitis B surface antigen
mechanism of inactivation by N^{α}-cocyl-L-arginine ethyl ester, 120
Hepatitis B virus
amphotericin B, 826
Herpes simplex virus type 1
1-β-D-arabinofuranosyl-*E*-5-(2-halogenovinyl)uracils, 47
latent, adenosine monophosphate in reactivation of, 547
quantitation in rabbit preocular tear film after acyclovir, 580
Herpes simplex virus type 2
acyclovir for rabbit neonatal infections, 503
High-performance liquid chromatography
moxalactam in human body fluids, 252
HR221
cefodizime, 760
Human interferon
human myeloblast cell culture, 5
production in cell cultures, 1, 5
Human lymphoblastoid cells (DG-75)
interferon production, 151
Human myeloblasts
interferon production, 5
Human polymorphonuclear leukocytes
microbicidal function, effects of drugs on, 15
Hydrogen peroxide
P. anaerobius, metabolic inhibition of, 726
4-Hydroxy-3-nitrosobenzaldehyde
mode of action, 558

Imidazoles, antimycotic
action mechanisms, 71
Influenza A
guanosine interference with ribavirin protection in mice, 477
Influenza type A viruses
carbodine, 769
Interferon
production by human lymphoblastoid cell line, 151
6β-Iodopenicillanic acid (UK-38,006)
β-lactamase inhibitor, 327
Isoflurane
inhibition of measles virus replication, 298

Kanamycin
levels in human gallbladder bile & wall, 515
Ketoconazole
action mechanisms compared, 71
bioassay in serum and cerebrospinal fluid, 59
neutrophil toxicity, 660
zygomycetes susceptibility, 688

β-Lactam antibiotics
activity vs. *Bacteroides* spp., compared, 433
competition for *N. gonorrhoeae* penicillin-binding proteins, 109
H. influenzae susceptibility, 208
new, comparative activity against anaerobes, 600
new, vs. *P. aeruginosa* in cystic fibrosis, 545
susceptibility of *N. gonorrhoeae* from pelvic inflammatory disease, 260
susceptibility of penicillin-resistant pneumococci, 204
synergy with amikacin vs. *P. aeruginosa* and *S. marcescens*, 239
β-Lactamase
cefuroxime and cefotaxime hydrolysis, 262
H. ducreyi susceptibility, 144
immunological properties, 262
6β-iodopenicillanic acid—an inhibitor, 327
N. gonorrhoeae, comparative in vitro drug activities, 681
Lactobacillus
prophylaxis for *E. coli* diarrhea, 104
Legionella pneumophila
intracellular, antimicrobial susceptibility, 691
Legionella spp.
susceptibility to 19 antimicrobial agents, 793

Measles virus
inhibition by enflurane and isoflurane in cells, 298
Mechanism of action
cinodine, 425
2,9-dimethyl-1,10-phenanthroline copper(I) complex, 455
4-hydroxy-3-nitrosobenzaldehyde, 558
panamycin in *S. aureus*, 443
Meningitis, experimental
trimethoprim-sulfamethoxazole, 81
Metabolic inhibition
hydrogen peroxide, 726
P. anaerobius, 726
Metronidazole
metabolism in *E. histolytica* and *T. vaginalis*, 410
Mezlocillin
disk diffusion susceptibility testing, tentative standards, 197
disposition in chronic hemodialysis patients, 590
enteral absorption in rabbits, 418
Miconazole
action mechanisms compared, 71
zygomycetes susceptibility, 688

MK-0366
comparative in vitro activity, 265
new oral antimicrobial agent, 265
MK0787
see *N*-formimidoyl thienamycin
Mouse arthritis
gentamicin, 321
M. pulmonis, tobramycin or gentamicin therapy, 321
tobramycin, 321
Mouse cytomegalovirus
acyclovir efficacy in vivo, 275
Moxalactam
biliary excretion, 231
clinical evaluation, 88
during hemodialysis, 398
epimers, activity and stability in vitro, 30
in human body fluids, determination methods, 252
in vitro efficacy, 642
multiple-dose pharmacokinetics, 567
ocular penetration in rabbits with staphylococcal endophthalmitis, 595
pharmacokinetics, 378, 398, 642
pharmacokinetics after intravenous infusion, 567
plus tobramycin, 539
protein binding, 378
protein penetration in *E. coli* mutants, 613
renal failure subjects, 378
therapy of cephalothin-resistant infections, 351
MS-2 susceptibility test system
disagreements with Autobac-1, 000
Mycobacterium avium
multiple drug resistance, 666
wall structure and drug exclusion, 666
Mycobacterium marinum
susceptibility to tetracyclines, aminoglycosides, 610
Mycobacterium smegmatis
ethambutol effects on lipids, 401
Mycobacterium tuberculosis
pyrazinamide susceptibility assay, 556
Mycoplasma gallisepticum
mode of action of 2,9-dimethyl-1,10-phenanthroline copper(I) complex, 455
Mycoplasma pulmonis
gentamicin for mouse arthritis, 321
tobramycin for mouse arthritis, 321

Neisseria gonorrhoeae
comparative activity of MK-0366 and other oral antibiotics, 265
comparative in vitro drug activities, 681
competition among β-lactams for penicillin-binding proteins, 109
β-lactam susceptibility of pelvic inflammatory disease isolates, 260
pelvic inflammatory disease, 260
penicillin G effects on peptidoglycans, 98
Netilimicin
compared in vitro with Win 42122-2, 247
Netilmicin
tissue accumulation in patients, 714
Neutrophils
effects of aminoglycosides on chemotaxis, 258
Nocardia asteroides
in vitro susceptibility
Cephalosporins, 841
N-Formimidoyl thienamycin, 841

Palmitoyl tuberactinamine N
drug-resistant mutants with altered ribosomes, 834
Pamamycin
mode of action in *S. aureus*, 443
Pasteurella multocida
conjugal transfer of R plasmids, 415
Pediatric patients
cefotaxime pharmacology, 487
Pelvic inflammatory disease
cefotazime, 847
N. gonorrhoeae isolates, β-lactam susceptibility, 260
Penicillin
pH-dependent tolerance of group B streptococci, 128
resistance plasmids in *S. epidermidis*, 359
resistant pneumococci, susceptibility to new β-lactams, 204
susceptibility of group A beta-hemolytic streptococci, 244
tolerance of human group C streptococci, 235
Penicillin-binding proteins
C. perfringens, 809
N. gonorrhoeae: β-lactams competition, 109
Penicillin G
effect on *N. gonorrhoeae* peptidoglycans, 98
gonococcal urethritis, 693
Penicillins
gram-positive bacteria, 843
H. influenzae, 843
Peptostreptococcus anaerobius
hydrogen peroxide, 726
metabolic inhibition, 726
Pharmacokinetics
amikacin
ventricular fluid and serum levels, 583
cefamandole, compared, 356
cefazolin and moxalactam after simultaneous infusion, 576
ceforanide, effect on probenecid on, 530
cefotaxime
multiple-dose, compared, 567
cefoxitin
renal clearance studies of patients with renal insufficiency, 741
ceftazidime
multiple-dose, compared, 567
ceftazidime, compared, 356
ceftriaxone in humans, 634
fosfomycin, 393
gentamicin
induced canine glomerulonephritis, 387
mezlocillin
chronic hemodialysis patients, 590
moxalactam, 642
hemodialysis, 398
multiple-dose, compared, 567
renal failure, 378, 398
tobramycin
influence of age, 587
YM09330, 176

Pharmacology
cefamandole, 366
cefotaxime, clinical, in children, 487
ceftizoxime, 366
Photochemical damage
retinoids, 699
unsaturated fatty acids, 699
Piperacillin
clinical evaluation, 481
gonococcal urethritis, 693
in vitro comparison with *N*-formimidoyl thienamycin, 140
penetration into cerebrospinal fluid, 481
Pittsburgh pneumonia agent (*Legionella micdadei*)
susceptibility to 19 antimicrobial agents, 793
Plasmids
S. epidermidis, penicillin and tetracycline resistance, 359
Pneumococci
penicillin resistant
susceptibility to new β-lactams, 204
Pneumonia
clinical trial with ceforanide, cefazolin, 648
Preocular tear film, rabbit
herpesvirus quantitation after acyclovir, 580
Probenecid
effect on ceforanide pharmacokinetics, 530
Prophylaxis
clindamycin, colonic microflora, 736
Lactobacillus, for *E. coli* diarrhea, 104
selective suppression of rectal flora in granulocytopenia, 620
Pseudomonas aeruginosa
activity of new β-lactams in cystic fibrosis, 545
cystic fibrosis patients, new β-lactams, 545
fortimicin A plus β-lactams, 33
gentamicin resistant, *N*-formimidoyl thienamycin activity, 702
β-lactam plus amikacin synergy, 239
moxalactam, cefotaxime, tobramycin serum activity, 539
Pyelonephritis, enterococcal
ampicillin, rifampin, streptomycin, in rats, 491
Pyocyanin
antibiotic action, 814
Pyrazinamidase
activity in *M. tuberculosis*, 556
Pyrazinamide
M. tuberculosis susceptibility assay, 556

Quindoxin and metabolites
mutagenicity, 336

Renal failure
moxalactam, 378, 398
Renal function
vancomycin disposition in rats, 718
Renal insufficiency
renal clearance studies of patients with renal insufficiency, 741
cefoxitin pharmacokinetics, 741
Retinoids
photochemical damage destroys virucidal activity, 699
Ribavirin
aerosol, versus influenza A in mice, 477
guanosine interference with antiviral protection in mice, 477
Ribonucleic acid polymerase
inhibition by a *B. fragilis* bacteriocin, 437
Rifampin
effect of mixing in staphylococcal activity assays, 267
plus ampicillin, streptomycin in rat pyelonephritis, 491
S. aureus variants, 709
Ro 13-9904
see Ceftriaxone
Rosaramicin
C. fetus subsp. *jejuni*, 850
U. urealyticum susceptibility testing, 53
Rosoxacin
uncomplicated gonorrhea, 625
R plasmids
chloramphenicol in *S. naestved* and *E. coli*, 382
conjugal transfer in *P. multocida*, 415
spread among urinary tract *E. coli*, 496
transposons for chloramphenicol resistance, 382

Saccharomyces cerevisiae
15-azasterol inhibition, effects, 184
SCE-1365
cefmenoxime, 747
see Cefmenoxime
Serratia marcescens
β-lactam plus amikacin synergy, 239
Serum
anaerobic plate drug assay, 678
gentamicin measurement, 821
ketoconazole bioassay, 59
tobramycin measurement, 821
Serum protein binding
cephalosporin penetration into interstitial fluid in humans, 783
Simian varicella
acyclovir treatment of experimental infection of monkeys, 291
Sodium polyanethol sulfonate
aminoglycoside inactivation, 272
Staphylococcal endophthalmitis
moxalactam ocular penetration in rabbits, 595
Staphylococci
rifampin activity, effect of mixing in assays, 267
Staphylococcus aureus
moxalactam, cefotaxime, tobramycin serum activity, 539
pamamycin mode of action, 443
rifampin-resistant variants, 709
Staphylococcus epidermidis
penicillin, tetracycline resistance plasmids, 359
Streptococcus faecalis
rifampin, ampicillin, streptomycin, 491
Streptococcus faecium
bacteriocin, 542
hemolysin, 542
Streptococcus pyogenes
adhesion to pharyngeal epithelial cells, 563
Streptococcus sanguis

experimental endocarditis, therapy, 10
Streptomyces clavuligerus
amoxicillin/clavulanic acid, 800
urinary tract infection, 800
Streptomyces fradiae
mutants blocked in tylosin biosynthesis, 214
Streptomycin
plus ampicillin, rifampin in rat pyelonephritis, 491
Streptovaricins
activities, 653
Sulfamethoxazole
agar dilution, 731
Bacteroides spp., 731
disk diffusion, 731
Susceptibility testing
Anderson Technical semiautomated system, 777
Autobac-1 and MS-2 results disagreements, 115
Susceptibility test methods
survey, 66
Synergy
alafosfalon plus cephalexin, 470
amikacin plus new β-lactams vs. *P. aeruginosa* and *S. marcescens*, 239
aminoglycoside plus penicillin in enterococcal endocarditis, 405
azlocillin, cefotaxime, amikacin, 463
clavulanic acid plus amoxicillin vs. *H. ducreyi*, 144
fortimicin A plus β-lactams vs. *P. aeruginosa*, 33
moxalactam, cefotaxime, tobramycin vs. *P. aeruginosa*, *S. aureus*, 539
P. aeruginosa: fortimicin A plus β-lactams, 33
rifampin, ampicillin, streptomycin in rat pyelonephritis, 491

Talampicillin
bioavailability, 837
Tetracycline
resistance plasmids in *S. epidermidis*, 359
uptake by *E. coli* membrane vesicles, 307
U. urealyticum susceptibility testing, 53
Tetracyclines
M. marinum susceptibility, 610
Thymidine kinase
antiviral nucleoside analog activity, 420
Ticarcillin
bioassay, 491
Tissue accumulation in patients
netilmicin, 714
Tobramycin
effect of patient age on pharmacokinetics, 587
measurement in serum, comparison of three methods, 821
mouse arthritis with *M. pulmonis*, 321
plus cefotaxime or moxalactam, 539
Toxicity
amphotericin B and its methyl ester, 660
ketoconazole, 660
Trichomonas vaginalis
metronidazole metabolism, 410
Trifluorothymidine
cytomegalovirus, assays, 286
Trimethoprim
agar dilution, 731
Bacteroides spp., 731
disk diffusion, 731
Trimethoprim-sulfamethoxazole
experimental *E. coli* meningitis in rabbits, 81
Tylosin
biosynthesis, 214
conversion enzymes, 370
macrolide antibiotic, 214
production in *S. fradiae*, 370
S. fradiae mutants, 214

Ureaplasma urealyticum
susceptibility testing, 53
Urinary tract infection
amoxicillin/clavulanic acid, 800
R plasmid spread among *E. coli* isolated from, 496
S. clavuligerus, 800

Vancomycin
disposition in rats with normal and abnormal renal functions, 718
Ventricular fluid
amikacin levels, 583
Virus inhibition assay
acyclovir levels in human plasma and urine, 787

Win 42122-2
in vitro comparison vs. gram-negative bacilli, 247

YM09330
new broad-spectrum cephamycin, 176
pharmacokinetics in experimental animals, 176

Zygomycetes
susceptibility to imidazoles, 688

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
July	10 July 1981	1–149
August	11 August 1981	151–279
September	11 September 1981	281–423
October	13 October 1981	425–562
November	4 December 1981	563–704
December	15 December 1981	705–853

ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 20

WASHINGTON, DC 20006

1981

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 20 ● 1981

EDITORIAL BOARD

Leon H. Schmidt, *Editor-in-Chief* (1985)
University of Alabama in Birmingham
Birmingham, Alabama

Herbert L. Ennis, *Editor* (1982)
Roche Institute of Molecular Biology
Nutley, New Jersey

George A. Jacoby, Jr., *Editor* (1985)
Massachusetts General Hospital
Boston, Massachusetts

Robert L. Hamill, *Editor* (1985)
Eli Lilly & Company, Inc.
Indianapolis, Indiana

John A. Washington II, *Editor* (1986)
Mayo Clinic
Rochester, Minnesota

Norris Allen (1983)
Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1983)
George R. Aronoff (1983)
Robert Austrian (1983)
Arthur L. Barry (1983)
John E. Bennett (1981)
Gerald P. Bodey (1983)
Robert E. Brummett (1982)
Lawrence E. Bryan (1982)
D. Buyske (1983)
C. Glenn Cobbs (1983)
Paul S. Cohen (1983)
Nigel A. C. Curtis (1983)
Naomi Datta (1981)
Lawrence E. Day (1983)
R. Gordon Douglas, Jr. (1983)
Theodore Eickhoff (1982)
Arthur English (1983)
David S. Feingold (1981)
Robert Fekety (1981)
Sydney Finegold (1982)
Robert J. Fitzgerald (1983)
Martin Forbes (1983)
Anthony J. Glazko (1981)
Irving H. Goldberg (1982)
Harry Gooder (1982)
Jack Gwaltney (1983)
Wendell H. Hall (1983)
Maurice W. Harmon (1981)
Michael Higgins (1983)
Ronald D. Hinsdill (1982)
Dah Hsi Wang Ho (1983)
Richard Hornick (1983)
L. H. Huang (1982)
Milton Huppert (1983)
George Gee Jackson (1983)
William J. Jusko (1983)
Donald Kaye (1982)
Jerome O. Klein (1982)
George S. Kobayashi (1982)
Donald J. Krogstad (1983)
Felix Leitner (1983)
Stephen A. Lerner (1983)
Matthew E. Levison (1981)
Stuart B. Levy (1983)
Friedrich C. Luft (1981)
Joan Lusk (1983)
R. Luthy (1983)
Gerald Medoff (1983)
Barbara Minshew (1982)
Robert C. Moellering, Jr. (1982)
R. B. Morin (1982)
Bernard Moss (1981)
John D. Nelson (1983)
Harold C. Neu (1983)
J. F. Niblack (1983)
T. J. Perun (1983)
Charles A. Plate (1982)
Burton M. Pogell (1981)
K. E. Price (1982)
Paul Quie (1983)
Michael Rein (1983)
W. H. G. Richards (1983)
Mark H. Richmond (1982)
Richard Roberts (1982)
Ian M. Rollo (1982)
Richard Root (1983)
John P. Rosazza (1983)
Jon E. Rosenblatt (1982)
Milton R. J. Salton (1981)
Merle Sande (1982)
Arthur K. Saz (1982)
Jerome J. Schentag (1982)
F. C. Sciavolino (1982)
Oldrich K. Sebek (1983)
William M. Shannon (1983)
Charles Shipman, Jr. (1982)
Robert W. Sidwell (1981)
Walter Siegenthaler (1983)
P. Frederick Sparling (1981)
Brian G. Spratt (1983)
R. Sutherland (1982)
Vera L. Sutter (1981)
Morton N. Swartz (1982)
Richard B. Sykes (1982)
Alexander Tomasz (1982)
Ralph Tompsett (1982)
Hamao Umezawa (1981)
Donald Van Harken (1982)
Michael Waring (1981)
Pamela Waterworth (1982)
Jerry A. Weisbach (1982)
Bernard Weisblum (1982)
Peter G. Welling (1982)
Richard Wenzel (1983)

Walter G. Peter III, *Managing Editor*
Gisella Pollock, *Assistant Managing Editor*
Deborah J. Shuman, *Production Editor*
1913 I St., NW, Washington, DC 20006

Frederick C. Neidhardt, *President* (1981–1982)
J. Mehsen Joseph, *Secretary*

John C. Sherris, *President-Elect* (1981–1982)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents, anticancer agents, and chemotherapy. Instructions to Authors are published in the January issue each year; reprints are available from the Editors and the Publications Office. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is $90 per year. The member subscription price is $25 per year. Single copies are $9. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

日本：価格は外貨表示とは関係なく円建。

Second class postage paid at Washington, DC 20006, and at additional mailing offices.
Made in the United States of America.
Copyright © 1981, American Society for Microbiology.
All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

Volume 20 Contents for July 1981 Number 1

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Cell Cultures Producing Human Interferon. PHILIP C. FAMILLETTI AND SIDNEY PESTKA* 1–4

Production of High Levels of Human Leukocyte Interferon from a Continuous Human Myeloblast Cell Culture. PHILIP C. FAMILLETTI, RUSSELL MCCANDLISS, AND SIDNEY PESTKA* 5–9

Heterogeneity of Action Mechanisms Among Antimycotic Imidazoles. INDER JIT SUD AND DAVID S. FEINGOLD* 71–74

New Plasmid-Mediated Aminoglycoside Adenylyltransferase of Broad Substrate Range That Adenylylates Amikacin. REGINALD G. COOMBE* AND ANTHONY M. GEORGE 75–80

Effect of Penicillin G on Release of Peptidoglycan Fragments by *Neisseria gonorrhoeae*: Characterization of Extracellular Products. RABINDRA K. SINHA AND RAOUL S. ROSENTHAL* 98–103

Competition of β-Lactam Antibiotics for the Penicillin-Binding Proteins of *Neisseria gonorrhoeae*. THOMAS J. DOUGHERTY,* ANTJE E. KOLLER, AND ALEXANDER TOMASZ 109–114

Mechanism of Inactivation of Hepatitis B Surface Antigen by N^{α}-Cocoyl-L-Arginine Ethyl Ester. YOSHIKAZU SUGIMOTO* AND SHIGESHI TOYOSHIMA 120–127

Physiological Effects and Microbial Susceptibility

Effect of Antimicrobial Agents on Human Polymorphonuclear Leukocyte Microbicidal Function. WILLIAM D. WELCH,* DAVE DAVIS, AND LAURI D. THRUPP 15–20

Fluorimetric Determination of Cefuroxime in Body Fluids. ZUHAIR HASHIM AL-RAWI AND SOAD TABAQCHALI* 25–29

Epimers of Moxalactam: In Vitro Comparison of Activity and Stability. R. WISE,* P. J. WILLS, AND K. A. BEDFORD 30–32

Synergistic Activities of Fortimicin A and β-Lactam Antibiotics Against *Pseudomonas aeruginosa*. KINYA YAMASHITA, HARUHIDE KAWABE, AND SUSUMU MITSUHASHI* 33–37

Antiherpesviral and Anticellular Effects of 1-β-D-Arabinofuranosyl-*E*-5-(2-Halogenovinyl)Uracils. HARUHIKO MACHIDA,* SHINJI SAKATA, AKIRA KUNINAKA, AND HIROSHI YOSHINO 47–52

Standardized Method for Determining Antimicrobial Susceptibility of Strains of *Ureaplasma urealyticum* and Their Response to Tetracycline, Erythromycin, and Rosaramicin. JANET A. ROBERTSON,* JOHN E. COPPOLA, AND OWEN R. HEISLER 53–58

Bactericidal Activity of Cefoperazone with CP-45,899 Against Large Inocula of β-Lactamase-Producing *Haemophilus influenzae*. PAULINE K. W. YU AND JOHN A. WASHINGTON II* 63–65

Quantitative Susceptibility Test Methods in Major United States Medical Centers. PATRICK R. MURRAY* AND JAMES H. JORGENSEN 66–70

Examination of Major Disagreements in Susceptibility Test Results by Autobac-1 and MS-2. NORMA J. LINDSEY* AND WILLIAM G. BARNES 115–119

pH-Dependent Penicillin Tolerance of Group B Streptococci. DIANE HORNE AND ALEXANDER TOMASZ* 128–135

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

CONTENTS

In Vitro Antimicrobial Activity of Ceftizoxime Against Glucose-Nonfermentative Gram-Negative Rods. EIKO YABUUCHI,* TOMIYOSHI ITO, EIKI TANIMURA, NORIMI YAMAMOTO, AND AKIO OHYAMA 136–139

In Vitro Comparison of *N*-Formimidoyl Thienamycin, Piperacillin, Cefotaxime, and Cefoperazone. VICTORIA A. TUTLANE,* RICHARD V. MCCLOSKEY, AND JUDITH A. TRENT 140–143

Synergistic Antibacterial Activity of Clavulanic Acid and Amoxicillin Against β-Lactamase-Producing Strains of *Haemophilus ducreyi*. YVES C. GIROUARD, IAN W. MACLEAN, ALLAN R. RONALD, AND WILLIAM L. ALBRITTON* 144–145

Absence of Tolerance to Cefoxitin in Anaerobic Bacteria. ELLIE J. C. GOLDSTEIN,* Y. Y. KWOK, AND VERA L. SUTTER 146–148

Pharmacology and Therapeutics

Experimental Endocarditis Caused by *Streptococcus sanguis*: Single and Combined Antibiotic Therapy. MARÍA V. VICENTE, TRÁNSITO OLAY, AND ANTONIO RODRÍGUEZ 10–14

Pharmacology, Safety, and Efficacy of Cefamandole in Childhood Infections. M. C. THIRUMOORTHI,* ADNAN S. DAJANI, CATHERINE V. VINCENT, AND MOLLY J. MAURER 21–24

BRL 17421, a Novel β-Lactam Antibiotic, Highly Resistant to β-Lactamases, Giving High and Prolonged Serum Levels in Humans. BRIAN SLOCOMBE,* MICHAEL J. BASKER, PETER H. BENTLEY, J. PETER CLAYTON, MARTIN COLE, KEITH R. COMBER, RONALD A. DIXON, ROBERT A. EDMONDSON, DERRICK JACKSON, DAVID J. MERRIKIN, AND ROBERT SUTHERLAND ... 38–46

Sensitive Bioassay for Ketoconazole in Serum and Cerebrospinal Fluid. J. H. JORGENSEN,* G. A. ALEXANDER, J. R. GRAYBILL, AND D. J. DRUTZ 59–62

Trimethoprim-Sulfamethoxazole Therapy of Experimental *Escherichia coli* Meningitis in Rabbits. JOSEPH M. MYLOTTE,* THEODORE R. BATES, KIM A. SERGEANT, RONALD E. MATSON, AND THOMAS R. BEAM, JR. 81–87

Clinical Evaluation of Moxalactam. W. K. LIVINGSTON,* A. M. ELLIOTT, W. E. DISMUKES, C. K. AVENT, AND C. G. COBBS ... 88–97

Lactobacillus Prophylaxis for Diarrhea Due to Enterotoxigenic *Escherichia coli*. MARY L. CLEMENTS,* MYRON M. LEVINE, ROBERT E. BLACK, ROY M. ROBINS-BROWNE, LUIS A. CISNEROS, GEORGE L. DRUSANO, CLAUDIO F. LANATA, AND ALFRED J. SAAH 104–108

Errata

Nogalamycin Inhibits Ribonucleic Acid Synthesis in Growing and Developing Cells of the Slime Mold *Dictyostelium discoideum*. HERBERT L. ENNIS 149

Ribosomal Binding Region for the Antibiotic Tiamulin: Stoichiometry, Subunit Location, and Affinity for Various Analogs. GREGOR HÖGENAUER AND CHRISTINE RUF 149

Volume 20 Contents for August 1981 Number 2

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Interferon Production by a Human Lymphoblastoid Cell Line (DG-75) Free of the Epstein-Barr Virus Genome. ARYE LAZAR,* SHAUL REUVENY, MOSHE MINAI, ABRAHAM TRAUB, AND AVSHALOM MIZRAHI 151–154

β-Lactamase Stability and Antibacterial Activity of Cefmenoxime (SCE-1365), a Novel Cephalosporin. KENJI OKONOGI,* MITSUZO KUNO, MAKOTO KIDA, AND SUSUMU MITSUHASHI 171–175

Physiological Response of *Saccharomyces cerevisiae* to 15-Azasterol-Mediated Growth Inhibition. R. J. RODRIGUEZ AND L. W. PARKS* 184–189

Properties of *Streptomyces fradiae* Mutants Blocked in Biosynthesis of the Macrolide Antibiotic Tylosin. RICHARD H. BALTZ* AND EUGENE T. SENO 214–225

Immunological Properties of Beta-Lactamases That Hydrolyze Cefuroxime and Cefotaxime. KEIJI HIRAI,* KENICHI SATO, NOBUYUKI MATSUBARA, RYOICHI KATSUMATA, MATSUHISA INOUE, AND SUSUMU MITSUHASHI 262–264

Physiological Effects and Microbial Susceptibility

Inhibition of Aminoglycoside Activity by Heparin. LENNART NILSSON,* ROLF MALLER, AND STEFFAN ÅNSÉHN 155–158

Rapid Detection of Chloramphenicol Resistance in *Haemophilus influenzae*. PARVIZ AZEMUN, TERRENCE STULL, MARILYN ROBERTS, AND ARNOLD L. SMITH* 168–170

Mezlocillin: Tentative Interpretive Standards for Disk Diffusion Susceptibility Testing. PETER C. FUCHS,* ARTHUR L. BARRY, CLYDE THORNSBERRY, RONALD N. JONES, AND E. HUGH GERLACH 197–203

Susceptibility of Pneumococci to 14 Beta-Lactam Agents: Comparison of Strains Resistant, Intermediate-Resistant, and Susceptible to Penicillin. JOEL I. WARD* AND ROBERT C. MOELLERING, JR. 204–207

Susceptibility of *Haemophilus influenzae* to Chloramphenicol and Eight Beta-Lactam Antibiotics. M. C. THIRUMOORTHI,* DENISE M. KOBOS, AND ADNAN S. DAJANI 208–213

Comparative In Vitro Study of New Cephalosporins. GERALD P. BODEY,* VICTOR FAINSTEIN, AND ANNE M. HINKLE 226–230

Penicillin Tolerance of Human Isolates of Group C Streptococci. DAVID PORTNOY,* JOHN PRENTIS, AND GEOFFREY K. RICHARDS 235–238

Comparative In Vitro Synergistic Activity of New Beta-Lactam Antimicrobial Agents and Amikacin Against *Pseudomonas aeruginosa* and *Serratia marcescens*. TERRANCE O. KURTZ, DREW J. WINSTON,* DAVID A. BRUCKNER, AND WILLIAM J. MARTIN 239–243

Susceptibility of Group A Beta-Hemolytic *Streptococcus* Isolates to Penicillin and Erythromycin. GREG R. ISTRE, DAVID F. WELCH,* MELVIN I. MARKS, AND NELSON MOYER 244–246

In Vitro Studies with Win 42122-2: Comparison with Gentamicin, Netilmicin, and Amikacin. CHRISTINE C. SANDERS* AND W. EUGENE SANDERS, JR. 247–251

Determination of Moxalactam in Human Body Fluids by Liquid Chromatographic and Microbiological Methods. DAVID J. MINER,* DENNIS L. COLEMAN, ALEXANDER M. M. SHEPHERD, AND THOMAS C. HARDIN 252–257

Effects of Aminoglycoside Antibiotics on Neutrophil Chemotaxis. FULVIO SACCHI,* GIANLUIGI MARSEGLIA, ANNA FIETTA, ANTONIETTA MARCHI, AND ANTONIO G. SICCARDI 258–259

Comparative In Vitro Activity of Mk-0366 and Other Selected Oral Antimicrobial Agents Against *Neisseria gonorrhoeae*. MOHAMMED Y. KHAN,* YOUSUF SIDDIQUI, AND ROBERT P. GRUNINGER 265–266

Effect of Mixing on Rifampin Bactericidal Activity Against Staphylococci. STEPHEN H. ZINNER,* MIREILLE HUSSON, AND JEAN KLASTERSKY 267–269

In Vitro Susceptibility of *Capnocytophaga* Strains to 18 Antimicrobial Agents. VERA L. SUTTER,* DENISE PYEATT, AND Y. Y. KWOK 270–271

Sodium Polyanethol Sulfonate Inactivation of Aminoglycosides. DONALD J. KROGSTAD,* PATRICK R. MURRAY, GEORGE G. GRANICH, ANN C. NILES, JACK H. LADENSON, AND J. E. DAVIS 272–274

Pharmacology and Therapeutics

In Vivo Activity of Ceftriaxone (Ro 13-9904), a New Broad-Spectrum Semisynthetic Cephalosporin. G. BESKID,* J. G. CHRISTENSON, R. CLEELAND, W. DELORENZO, AND P. W. TROWN 159–167

Pharmacokinetics of a New Broad-Spectrum Cephamycin, YM09330, Parenterally Administered to Various Experimental Animals. M. KOMIYA, Y. KIKUCHI, A. TACHIBANA,* AND K. YANO 176–183

Influence of Study Design in Assessing Food Effects on Absorption of Erythromycin Base and Erythromycin Stearate. ANTHONY R. DISANTO* AND DALE J. CHODOS 190–196

Biliary Excretion of Moxalactam. OCTAVIO V. MARTINEZ,* JOE U. LEVI, ALAN LIVINGSTONE, THEODORE I. MALININ, ROBERT ZEPPA, DUANE HUTSON, AND NINA EINHORN 231–234

β-Lactam Susceptibility of *Neisseria gonorrhoeae* Isolates from Pelvic Inflammatory Disease. GEORGES PINON,* ROLAND QUENTIN, PATRICE LAUDAT, AND ROBERT VARGUES 260–261

Efficacy of Acyclovir Against Mouse Cytomegalovirus In Vivo. JOHN R. WINGARD,* WILLIAM J. BENDER, REIN SARAL, AND WILLIAM H. BURNS 275–278

Errata

Anti-*Pseudomonas* Activity in Bronchial Secretions of Patients Receiving Amikacin or Tobramycin as a Continuous Infusion. G. MOMBELLI, L. COPPENS, J. P. THYS, AND J. KLASTERSKY 279

Activity of Ceftazidime (GR 20263) Against Nosocomially Important Pathogens. J. M. T. HAMILTON-MILLER AND W. BRUMFITT 279

Volume 20 Contents for September 1981 Number 3

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Resistance to Tetracycline, Erythromycin, and Clindamycin in the *Bacteroides fragilis* Group: Inducible Versus Constitutive Tetracycline Resistance. GAETANO PRIVITERA, FRANÇOISE FAYOLLE, AND MADELEINE SEBALD* 314–320

Mutagenicity of Quindoxin, Its Metabolites, and Two Substituted Quinoxaline-Di-*N*-Oxides. LOTHAR BEUTIN,* ELENA PRELLER, AND BERNADETTE KOWALSKI 336–343

Aminoglycoside Phosphotransferase-Mediated Amikacin Resistance in *Escherichia coli*. GER P. A. BONGAERTS* AND G. MARJA P. KAPTIJN 344–350

Penicillin and Tetracycline Resistance Plasmids in *Staphylococcus epidermidis*. PAT A. TOTTEN,* LUCY VIDAL, AND JACK N. BALDWIN 359–365

Properties of *S*-Adenosyl-L-Methionine:Macrocin *O*-Methyltransferase in Extracts of *Streptomyces fradiae* Strains Which Produce Normal or Elevated Levels of Tylosin and in Mutants Blocked in Specific *O*-Methylations. EUGENE T. SENO AND RICHARD H. BALTZ* 370–377

Chloramphenicol Transposons Found in *Salmonella naestved* and *Escherichia coli* of Domestic Animal Origin. NOBUYUKI TERAKADO,* TSUTOMU SEKIZAKI, KAZUNORI HASHIMOTO, SOMAY YAMAGATA, AND TOMOKO YAMAMOTO 382–386

Effects of Ethambutol on Accumulation and Secretion of Trehalose Mycolates and Free Mycolic Acid in *Mycobacterium smegmatis*. JAMES O. KILBURN* AND KUNI TAKAYAMA 401–404

Metronidazole Metabolism in Cultures of *Entamoeba histolytica* and *Trichomonas vaginalis*. BERNARD B. BEAULIEU, JR., MARTHA A. MCLAFFERTY, RONALD L. KOCH, AND PETER GOLDMAN* 410–414

Conjugal Transfer of an R-Plasmid in *Pasteurella multocida*. DWIGHT C. HIRSH,* LORI D. MARTIN, AND KEITH R. RHOADES 415–417

Differential Activity of Potential Antiviral Nucleoside Analogs on Herpes Simplex Virus-Induced and Human Cellular Thymidine Kinases. Y.-C. CHENG,* G. DUTSCHMAN, J. J. FOX, K. A. WATANABE, AND H. MACHIDA 420–423

Physiological Effects and Microbial Susceptibility

Antagonism of Ampicillin and Chloramphenicol for Meningeal Isolates of Group B Streptococci. JANIS L. WEEKS, EDWARD O. MASON, JR., AND CAROL J. BAKER* 281–285

Activity of Trifluorothymidine Against Cytomegalovirus. JOHN R. WINGARD,* ROBERT K. STUART, REIN SARAL, AND WILLIAM H. BURNS 286–290

Inhibiting Effects of Enflurane and Isoflurane Anesthesia on Measles Virus Replication: Comparison with Halothane. PAUL R. KNIGHT,* MICHAEL L. NAHRWOLD, AND ELLIOTT BEDOWS 298–306

Active Uptake of Tetracycline by Membrane Vesicles from Susceptible *Escherichia coli*. LAURA M. MCMURRY,* JOANNE C. CULLINANE, RICHARD E. PETRUCCI, JR., AND STUART B. LEVY 307–313

6β-Iodopenicillanic Acid (UK-38,006), a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactam Compounds: Initial Bacteriological Characterization. BRIAN A. MOORE* AND KEITH W. BRAMMER 327–331

In Vitro Activity of Ceftizoxime Against *Bacteroides fragilis*: Comparison with Benzylpenicillin, Cephalothin, and Cefoxitin. ADRIAN ELEY AND DAVID GREENWOOD* 332–335

Pharmacology and Therapeutics

Acyclovir Treatment of Experimental Simian Varicella Infection of Monkeys. KENNETH F. SOIKE,* AMBHAN D. FELSENFELD, AND PETER J. GERONE 291–297

Curative Effects of Tobramycin or Gentamicin Therapy on Mouse Arthritis Caused by *Mycoplasma pulmonis*. RONALD A. DIXON 321–326

Moxalactam Therapy of Infections Caused by Cephalothin-Resistant Bacteria: Influence of Serum Inhibitory Activity on Clinical Response and Acquisition of Antibiotic Resistance During Therapy. RICHARD PLATT,* SANDRA L. EHRLICH, JOANNE AFARIAN, THOMAS F. O'BRIEN, JAMES E. PENNINGTON, AND EDWARD H. KASS 351–355

Comparison of Ceftazidime and Cefamandole Pharmacokinetics and Blister Fluid Concentrations. G. C. ARMSTRONG, R. WISE,* R. M. BROWN, AND J. HANCOX 356–358

Pharmacology of Ceftizoxime Compared with That of Cefamandole. HAROLD C. NEU* AND SUBRAMANIAM SRINIVASAN 366–369

Pharmacokinetics, Protein Binding, and Predicted Extravascular Distribution of Moxalactam in Normal and Renal Failure Subjects. LANCE R. PETERSON,* BONNIE BEAN, CLAUDINE E. FASCHING, WILLIAM P. KORCHIK, AND DALE N. GERDING 378–381

Gentamicin Pharmacokinetic Changes in Induced Acute Canine Nephrotoxic Glomerulonephritis. J. EDMOND RIVIERE,* GORDON L. COPPOC, EDWARD J. HINSMAN, AND WILLIAM W. CARLTON 387–392

Fosfomycin Kinetics After Intravenous and Oral Administration to Human Volunteers. MITSUYOSHI GOTO,* MASATOSHI SUGIYAMA, SHINJI NAKAJIMA, AND HAJIME YAMASHINA 393–397

Pharmacokinetics of Moxalactam in Patients with Renal Failure and During Hemodialysis. SUBRAMANIAM SRINIVASAN AND HAROLD C. NEU 398–400

Minimal Concentrations of Aminoglycoside That Can Synergize with Penicillin in Enterococcal Endocarditis. JAIME CARRIZOSA AND MATTHEW E. LEVISON* 405–409

Mezlocillin Enteral Absorption in Rabbits. KEVIN J. LAVELLE, MICHAEL E. BRIER, AND GEORGE R. ARONOFF* 418–419

Volume 20 Contents for October 1981 **Number 4**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Mechanism of Action of Cinodine, a Glycocinnamoylspermidine Antibiotic. MICHAEL GREENSTEIN,* JOHN L. SPETH, AND WILLIAM M. MAIESE 425–432

Inhibition of Ribonucleic Acid Polymerase by a Bacteriocin from *Bacteroides fragilis*. KEVIN G. MOSSIE, FRANK T. ROBB, DAVID T. JONES, AND DAVID R. WOODS* 437–442

Mode of Action of Pamamycin in *Staphylococcus aureus*. WEN-GANG CHOU AND BURTON M. POGELL* 443–454

Mode of Action of the Copper(I) Complex of 2,9-Dimethyl-1,10-Phenanthroline on *Mycoplasma gallisepticum*. HENDRIK SMIT, HENDERIKUS VAN DER GOOT,* WIJBE T. NAUTA, HENK TIMMERMAN, MARTINUS W. G. DE BOLSTER, AART-GERRIT JOCHEMSEN, ADRIAN H. STOUTHAMER, AND RONALD D. VIS 455–462

Spread of R-Plasmids Among *Escherichia coli* Causing Urinary Tract Infections. COLIN HUGHES,* EVA BAUER, AND ANTHONY P. ROBERTS 496–502

Arginine Regulation of Gramicidin S Biosynthesis. AGNÈS POIRIER AND ARNOLD L. DEMAIN* 508–514

Metabolism of Acyclovir in Virus-Infected and Uninfected Cells. PHILLIP A. FURMAN,* PAULO DE MIRANDA, MARTY H. ST. CLAIR, AND GERTRUDE B. ELION 518–524

Bacteriocin and Hemolysin from *Streptococcus faecium*. SHIZUTOSHI NAKAGAWA AND YOSHIYASU MATSUO* 542–544

Mutants of *Escherichia coli* That Are Resistant to Certain Beta-Lactam Compounds Lack the *ompF* Porin. KAREN J. HARDER, HIROSHI NIKAIDO,* AND MICHIO MATSUHASHI 549–552

Mode of Antibiotic Action of 4-Hydroxy-3-Nitrosobenzaldehyde from *Streptomyces viridans*. CHIEN-CHIN YANG AND JOHN LEONG* 558–562

Physiological Effects and Microbial Susceptibility

In Vitro Activity of MK0787 (*N*-Formimidoyl Thienamycin) and Other Beta-Lactam Compounds Against *Bacteroides* spp. M. NASU, J. P. MASKELL,* R. J. WILLIAMS, AND J. D. WILLIAMS 433–436

Antibacterial Properties of Alafosfalin Combined with Cephalexin. FRANK R. ATHERTON, MICHAEL J. HALL, CEDRIC H. HASSALL,* SIMON W. HOLMES, ROBERT W. LAMBERT, WILLIAM J. LLOYD, LOUIS J. NISBET, PETER S. RINGROSE, AND DONALD WESTMACOTT 470–476

Ticarcillin Bioassay. ROBERT M. BANNATYNE* AND ROSE CHEUNG 493–495

Cefsulodin: Antibacterial Activity and Tentative Interpretive Zone Standards for the Disk Susceptibility Test. A. L. BARRY,* R. N. JONES, AND C. THORNSBERRY 525–529

Inhibition of Bluetongue and Colorado Tick Fever Orbiviruses by Selected Antiviral Substances. DONALD F. SMEE, ROBERT W. SIDWELL,* SCOTT M. CLARK, B. B. BARNETT, AND REX S. SPENDLOVE 533–538

Serum Bactericidal Activity of Moxalactam and Cefotaxime With and Without Tobramycin Against *Pseudomonas aeruginosa* and *Staphylococcus aureus*. H. LAGAST, S. H. ZINNER, AND J. KLASTERSKY* 539–541

Activities of New Beta-Lactam Antibiotics Against Isolates of *Pseudomonas aeruginosa* from Patients with Cystic Fibrosis. ALICE S. PRINCE AND HAROLD C. NEU* 545–546

Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and *N*-Formimidoyl Thienamycin. CHARLES E. CHERUBIN,* MICHAEL L. CORRADO, MARCELINO F. SIERRA, MYLES E. GOMBERT, AND MICHAEL SHULMAN 553–555

Use of Pyrazinamidase Activity in *Mycobacterium tuberculosis* as a Rapid Method for Determination of Pyrazinamide Susceptibility. J. KENNETH MCCLATCHY,* ANNA Y. TSANG, AND MARK S. CERNICH 556–557

Pharmacology and Therapeutics

In Vitro and In Vivo Studies of Three Antibiotic Combinations Against Gram-Negative Bacteria and *Staphylococcus aureus*. S. H. ZINNER, J. KLASTERSKY,* H. GAYA, C. BERNARD, J. C. RYFF, AND THE EORTC ANTIMICROBIAL THERAPY PROJECT GROUP 463–469

Lack of Interference of Guanosine with Ribavirin Aerosol Treatment of Influenza A Infection in Mice. VERNON KNIGHT,* SAMUEL Z. WILSON, DAVID W. ALLING, REBECCA V. MOORE, AND ROSE M. LONGORIA 477–480

Clinical Evaluation of Piperacillin with Observations on Penetrability into Cerebrospinal Fluid. GORDON M. DICKINSON,* DAVID G. DROLLER, RICHARD L. GREENMAN, AND THOMAS A. HOFFMAN 481–486

Clinical Pharmacology of Cefotaxime in Pediatric Patients. DIMITRIS A. KAFETZIS, D. CRAIG BRATER,* JOHN KANARIOS, CONSTANTINE A. SINANIOTIS, AND CONSTANTINE J. PAPADATOS 487–490

Rifampin, Ampicillin, Streptomycin, and Their Combinations in the Treatment of Enterococcal Pyelonephritis in Rats. PHYLLIS A. OILL,* GEORGE M. KALMANSON, AND LUCIEN B. GUZE 491–492

Acyclovir Therapy of Neonatal Herpes Simplex Virus Type 2 Infections in Rabbits. STEVEN E. SICHER AND JANG O. OH* 503–507

Concentrations of Kanamycin and Amikacin in Human Gallbladder Bile and Wall. JOHN F. HANSBROUGH,* JAMES E. CLARK, AND LARRY G. REIMER 515–517

Failure of Probenecid to Alter the Pharmacokinetics of Ceforanide. JOHN F. JOVANOVICH, LOUIS D. SARAVOLATZ,* KEITH BURCH, AND DONALD J. POHLOD 530–532

Effects of Adenosine Monophosphate on the Reactivation of Latent Herpes Simplex Virus Type 1 Infections of Mice. WILLIAM T. BLUE,* ROGER D. WINLAND, DARLENE G. STOBBS, DONNY F. KIRKSEY, AND RUSSELL E. SAVAGE 547–548

Volume 20 Contents for November 1981 **Number 5**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Effect of Subinhibitory Concentrations of Antibiotics on the Adhesion of *Streptococcus pyogenes* to Pharyngeal Epithelial Cells. STANISLAWA TYLEWSKA,* STELLAN HJERTÉN, AND TORKEL WADSTRÖM 563–566

Penetration of Moxalactam Into Its Target Proteins in *Escherichia coli* K-12: Comparison of a Highly Moxalactam-Resistant Mutant with Its Parent Strain. YOSHIHIDE KOMATSU,* KAZUHISA MURAKAMI, AND TOHRU NISHIKAWA 613–619

Inhibition of Cellular and Virus-Associated Nucleotide Polymerases by, and Anti-Herpes Simplex Virus of, Streptovaricin Derivatives. B. I. SAHAI SRIVASTAVA,* RICHARD A. DICIOCCIO, KAILASH C. CHADHA, AND K. L. RINEHART, JR. 653–659

Multiple Drug Resistance in *Mycobacterium avium*: Is the Wall Architecture Responsible for the Exclusion of Antimicrobial Agents? NALIN RASTOGI,* CLAUDE FREHEL, ANTOINETTE RYTER, HÉLÈNE OHAYON, MAURICE LESOURD, AND HUGO L. DAVID 666–677

Photochemical Destruction of the Virucidal Activities of Retinoids and Unsaturated Fatty Acids. JEFFREY A. SANDS 699–701

Physiological Effects and Microbial Susceptibility

Comparative In Vitro Activity of New Beta-Lactam Antibiotics Against Anaerobic Bacteria. RIAL D. ROLFE* AND SYDNEY M. FINEGOLD 600–609

Susceptibility of *Mycobacterium marinum* to Tetracyclines and Aminoglycosides. RICHARD J. WALLACE, JR.,* AND KAREN WISS 610–612

Ketoconazole, Amphotericin B, and Amphotericin B Methyl Ester: Comparative In Vitro and In Vivo Toxicological Effects on Neutrophil Function. DANIEL J. MARMER,* BRANCH T. FIELDS, JR., GENE L. FRANCE, AND RUSSELL W. STEELE 660–665

Anaerobic Plate Method for Assaying Antimicrobial Agents in Serum. JOHN S. SMITH* AND JOHN H. NGUI-YEN 678–680

Comparative In Vitro Activity of Cefmenoxime, Cefotaxime, Cefuroxime, Cefoxitin, and Penicillin Against *Neisseria gonorrhoeae*. MOHAMMED Y. KHAN,* YOUSUF SIDDIQUI, MARGARET L. SIMPSON, AND ROBERT P. GRUNINGER 681–682

Comparative In Vitro Activity of Ceftizoxime, Cefoperazone, and Cefoxitin Against Anaerobic Bacteria. MURRAY W. DRULAK AND ANTHONY W. CHOW* 683–685

Susceptibility of Zygomycetes to Amphotericin B, Miconazole, and Ketoconazole. ROBERT H. K. ENG,* AUDREY PERSON, CAROLINA MANGURA, HERMAN CHMEL, AND MICHAEL CORRADO 688–690

Antimicrobial Susceptibility of Intracellular *Legionella pneumophila*. MARGARET A. BACHESON, HARVEY M. FRIEDMAN,* AND CHARLES E. BENSON 691–692

Evaluation of a Direct Blood Culture Disk Diffusion Antimicrobial Susceptibility Test. GARY V. DOERN,* DAVID R. SCOTT, ABDEL L. RASHAD, AND KENNETH S. KIM 696–698

Superior Activity of *N*-Formimidoyl Thienamycin Against Gentamicin-Resistant *Pseudomonas aeruginosa*. PAUL R. MICHAEL, ROBERT H. ALFORD,* AND ZELL A. MCGEE 702–704

Pharmacology and Therapeutics

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime. RUEDI LÜTHY,* JÜRG BLASER, ANTONIO BONETTI, HANSPETER SIMMEN, RICHARD WISE, AND WALTER SIEGENTHALER 567–575

Cefazolin and Moxalactam Pharmacokinetics After Simultaneous Intravenous Infusion. RON E. POLK,* BERRY J. KLINE, AND SHELDON M. MARKOWITZ 576–579

Quantitation of Herpes Simplex Virus Type 1 Shed in Preocular Tear Film of Rabbits Treated with Acyclovir. MARY T. GREEN,* EDMUND C. DUNKEL, AND BRIAN L. MORRIS 580–582

Intraventricular Levels of Amikacin After Intravenous Administration. RAM YOGEV* AND WILLIAM M. KOLLING 583–586

Influence of Age on Tobramycin Pharmacokinetics in Patients with Normal Renal Function. LARRY A. BAUER* AND ROBERT A. BLOUIN 587–589

Mezlocillin Disposition in Chronic Hemodialysis Patients. DAVID M. JANICKE, ANTOINETTE MANGIONE, ROBERT W. SCHULTZ, AND WILLIAM J. JUSKO* 590–594

Penetration of Ocular Tissues and Fluids by Moxalactam in Rabbits with Staphylococcal Endophthalmitis. ANNE KANE, MICHAEL BARZA,* AND JULES BAUM 595–599

Selective Suppression of Alimentary Tract Microbial Flora as Prophylaxis During Granulocytopenia. MICHAEL T. HARGADON, VIOLA M. YOUNG, STEPHEN C. SCHIMPFF,* JAMES C. WADE, AND GLENN E. MINAH 620–624

Treatment of Uncomplicated Gonorrhea with Rosoxacin. H. HUNTER HANDSFIELD,* FRANKLYN N. JUDSON, AND KING K. HOLMES 625–629

Chronic Salmonella Bacteriuria with Intermittent Bacteremia Treated with Low Doses of Amoxicillin or Ampicillin. SAMIR B. BASSILY,* MICHAEL E. KILPATRICK, ZOHEIR FARID, ISIS A. MIKHAIL, AND NABIL A. EL-MASRY 630–633

Pharmacokinetics of Ceftriaxone in Humans. I. H. PATEL,* S. CHEN, M. PARSONNET, M. R. HACKMAN, M. A. BROOKS, J. KONIKOFF, AND S. A. KAPLAN 634–641

In Vitro Activity, Efficacy, and Pharmacology of Moxalactam, a New β-Lactam Antibiotic. RICHARD SNEPAR, GEORGE POPORAD, JOSEPH ROMANO, AND MATTHEW E. LEVISON* 642–647

Ceforanide and Cefazolin Therapy of Pneumonia: Comparative Clinical Trial. RICHARD J. WALLACE, JR.,* R. RUSSELL MARTIN, FRANK J. QUINONES, AND STEPHEN B. GREENBERG 648–652

Effect of Filtration on Antimicrobial Solutions. PATRICK R. MURRAY* AND ANN C. NILES 686–687

Comparative Efficacy of Piperacillin and Penicillin G in Treatment of Gonococcal Urethritis. STEPHAN J. LANDIS, REUBEN RAMPHAL, BERNARD J. MANSHEIM, KENNETH H. RAND, AND JOSEPH W. SHANDS, JR.* 693–695

Volume 20 Contents for December 1981 **Number 6**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Metabolic Inhibition of *Peptostreptococcus anaerobius* Decreases the Bactericidal Effect of Hydrogen Peroxide. GÖRAN K. NYBERG AND JAN CARLSSON* 726–730

Role of the Membrane Potential in Bacterial Resistance to Aminoglycoside Antibiotics. P. DIANNE DAMPER AND WOLFGANG EPSTEIN* 803–808

Activity of Di-β-Lysyl-Capreomycin IIA and Palmitoyl Tuberactinamine N Against Drug-Resistant Mutants with Altered Ribosomes. TAKESHI YAMADA,* TADASHI TESHIMA, AND TETSUO SHIBA 834–836

Physiological Effects and Microbial Susceptibility

Effect of Carbon Dioxide on In Vitro Susceptibility of Anaerobic Bacteria to Erythromycin. ELLIE J. C. GOLDSTEIN,* VERA L. SUTTER, YUNG-YUAN KWOK, ROBERT P. LEWIS, AND SYDNEY M. FINEGOLD 705–708

Characteristics of Rifampin-Resistant Variants Obtained from Clinical Isolates of *Staphylococcus aureus*. DAVID R. MOORMAN AND GERALD L. MANDELL* 709–713

Factors Affecting the In Vitro Activity of Cefoperazone Against the *Bacteroides fragilis* Group. VERA L. SUTTER* AND Y. Y. KWOK 723–725

Agar Dilution Susceptibility of *Bacteroides* spp. to Sulfamethoxazole and Trimethoprim: Correlation with a Disk Diffusion Technique. THOMAS V. RILEY 731–735

Cefmenoxime (SCE-1365), a New Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretative Criteria. PETER C. FUCHS,* RONALD N. JONES, CLYDE THORNSBERRY, ARTHUR L. BARRY, E. HUGH GERLACH, AND HERBERT M. SOMMERS 747–759

In Vitro Antimicrobial Activity Evaluation of Cefodizime (HR221), a New Semisynthetic Cephalosporin. RONALD N. JONES,* ARTHUR L. BARRY, CLYDE THORNSBERRY, AND HAROLD W. WILSON 760–768

Laboratory Evaluation of the Anderson Technical Semiautomated Susceptibility Testing System. GEOFFREY A. MCKINLEY, DIANE J. FAGERBERG,* AND BEVERLY A. GEORGE 777–782

Susceptibility of Pittsburgh Pneumonia Agent (*Legionella micdadei*) and Other Newly Recognized Members of the Genus *Legionella* to Nineteen Antimicrobial Agents. A. W. PASCULLE,* J. N. DOWLING, R. S. WEYANT, J. M. SNIFFEN, L. G. CORDES, G. M. GORMAN, AND J. C. FEELEY 793–799

Penicillin-Binding Proteins in *Clostridium perfringens*. TIMOTHY F. MURPHY,* MICHAEL BARZA, AND JAMES T. PARK 809–813

Antibiotic Action of Pyocyanin. STEPHEN S. BARON AND JOHN J. ROWE* 814–820

Comparative Evaluation of Three Methods for Measuring Gentamicin and Tobramycin in Serum. JOHN H. NGUI-YEN, TIM HOFMANN, MARGARET WIGMORE, AND JOHN A. SMITH* 821–825

Effects of Amphotericin B on Hepatitis B Virus. HAROLD A. KESSLER,* JILL DIXON, COLIN R. HOWARD, KWESI TSIQUAYE, AND ARIE J. ZUCKERMAN 826–833

In Vitro Susceptibility of *Nocardia asteroides* to *N*-Formimidoyl Thienamycin and Several Cephalosporins. MICHAEL H. CYNAMON* AND GREGORY S. PALMER 841–842

Comparative Activity of Mezlocillin, Penicillin, Ampicillin, Carbenicillin, and Ticarcillin Against Gram-Positive Bacteria and *Haemophilus influenzae*. CHRISTINE C. SANDERS 843–846

In Vitro Susceptibility of *Campylobacter fetus* subsp. *jejuni* to *N*-Formimidoyl Thienamycin, Rosaramicin, Cefoperazone, and Other Antimicrobial Agents. VINCENT I. AHONKHAI,* CHARLES E. CHERUBIN, MARCELINO F. SIERRA, VICTOR D. BOKKENHEUSER, MICHAEL A. SHULMAN, AND ANNE C. MOSENTHAL 850–851

Susceptibility of *Clostridium septicum* to 23 Antimicrobial Agents. ELIZABETH L. GABAY,* RIAL D. ROLFE, AND SYDNEY M. FINEGOLD 852–853

Pharmacology and Therapeutics

Predicted Tissue Accumulation of Netilmicin in Patients. DAVID J. EDWARDS, ANTOINETTE MANGIONE, THOMAS J. CUMBO, AND JEROME J. SCHENTAG* 714–717

Comparison of Vancomycin Disposition in Rats with Normal and Abnormal Renal Functions. MEHER S. ENGINEER, DAH-HSI W. HO,* AND GERALD P. BODEY, SR. 718–722

Effect of Clindamycin Prophylaxis on the Colonic Microflora in Patients Undergoing Colorectal Surgery. L. KAGER, L. LILJEQVIST, A. S. MALMBORG, AND C. E. NORD* 736–740

Cefoxitin Pharmacokinetics: Relation to Three Different Renal Clearance Studies in Patients with Various Degrees of Renal Insufficiency. DIETER KAMPF,* RANDOLF SCHURIG, INGE KORSUKEWITZ, AND OSWALD BRÜCKNER 741–746

Evaluation of Carbodine, the Carbocyclic Analog of Cytidine, and Related Carbocyclic Analogs of Pyrimidine Nucleosides for Antiviral Activity Against Human Influenza Type A Viruses. WILLIAM M. SHANNON,* GUSSIE ARNETT, LOUISE WESTBROOK, Y. FULMER SHEALY, C. ALLEN O'DELL, AND R. WALLACE BROCKMAN 769–776

Influence of Serum Protein Binding and Mode of Administration on Penetration of Five Cephalosporins into Subcutaneous Tissue Fluid in Humans. BJÖRN HOFFSTEDT* AND MATS WALDER 783–786

Virus Inhibition Assay for Measurement of Acyclovir Levels in Human Plasma and Urine. D. F. MOORE, S. C. TAYLOR, AND Y. J. BRYSON* 787–792

Amoxicillin-Clavulanic Acid in Treatment of Urinary Tract Infection Due to Gram-Negative Bacteria Resistant to Penicillin. REINALDO MARTINELLI,* ANTÔNIO ALBERTO DA SILVA LOPES, MOEMA M. G. DE OLIVEIRA, AND HEONIR ROCHA 800–802

Bioavailability of Bacampicillin and Talampicillin, Two Oral Prodrugs of Ampicillin. JAN SJÖVALL,* LENNART MAGNI, AND ERIK VINNARS 837–838

Dose-Ranging Study of Ceftriaxone for Uncomplicated Gonorrhea in Men. H. HUNTER HANDSFIELD,* VICTORY L. MURPHY, AND KING K. HOLMES 839–840

Cefotaxime Treatment of Pelvic Inflammatory Disease. THOMAS P. MONSON,* TIMOTHY T. MILLER, AND CHARLES M. NOLAN 847–849